,coef,coef_graph,coef_combined,coef_combined_zscore,coef_combined2
5-Phosphoribose 1-diphosphate biosynthesis,1.4138069e-06,2.0,1.4138069e-06,-0.26553205,0.22452915
A tetrasaccharide linker sequence is required for GAG synthesis,0.01317251,14.0,0.01317251,-0.06420544,-0.09842661
ABC transporters in lipid homeostasis,0.0011686452,11.0,0.0011686452,-0.24769033,-0.11734053
ADP signalling through P2Y purinoceptor 1,0.020575121,19.0,0.020575121,0.04894707,-0.21108831
ADP signalling through P2Y purinoceptor 12,0.021094237,17.0,0.021094237,0.056882,-0.12621142
AKT phosphorylates targets in the cytosol,0.10863008,14.0,0.10863008,1.39491,0.9935858
AKT phosphorylates targets in the nucleus,0.0022835436,9.0,0.0022835436,-0.23064859,-0.025648024
AKT-mediated inactivation of FOXO1A,0.00014724211,5.0,0.00014724211,-0.26330298,0.10778988
ALKBH2 mediated reversal of alkylation damage,0.0015740223,2.0,0.0015740223,-0.24149396,0.24251941
ALKBH3 mediated reversal of alkylation damage,0.00019500346,4.0,0.00019500346,-0.26257294,0.14780542
AMPK inhibits chREBP transcriptional activation activity,0.015175275,7.0,0.015175275,-0.03359221,0.20076872
APC truncation mutants are not K63 polyubiquitinated,3.869615e-06,2.0,3.869615e-06,-0.26549453,0.22455722
APC truncation mutants have impaired AXIN binding,0.0012900895,11.0,0.0012900895,-0.24583401,-0.11595122
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1,0.021289635,45.0,0.021289635,0.059868768,-1.2291129
APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway,0.00041076157,6.0,0.00041076157,-0.25927496,0.0713353
APOBEC3G mediated resistance to HIV-1 infection,0.0023181518,4.0,0.0023181518,-0.23011959,0.17209373
ARL13B-mediated ciliary trafficking of INPP5E,0.0115703875,3.0,0.0115703875,-0.08869466,0.31740636
ATF4 activates genes,0.016706707,4.0,0.016706707,-0.010183522,0.33669546
ATF6 (ATF6-alpha) activates chaperone genes,0.023401482,6.0,0.023401482,0.09214937,0.3343438
ATP sensitive Potassium channels,2.4552068e-05,3.0,2.4552068e-05,-0.26517838,0.18532465
AUF1 (hnRNP D0) binds and destabilizes mRNA,0.039877687,34.0,0.039877687,0.34399617,-0.582309
AURKA Activation by TPX2,0.0182162,50.0,0.0182162,0.012889816,-1.4616182
AXIN missense mutants destabilize the destruction complex,7.6806e-05,11.0,7.6806e-05,-0.26437965,-0.12983091
Abacavir metabolism,0.028973758,3.0,0.028973758,0.17732432,0.51649684
Abacavir transmembrane transport,1.2160696e-05,2.0,1.2160696e-05,-0.26536778,0.22465208
Abasic sugar-phosphate removal via the single-nucleotide replacement pathway,0.00018248733,2.0,0.00018248733,-0.26276425,0.22660057
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,0.0011550905,2.0,0.0011550905,-0.24789755,0.23772693
Acetylation,0.0,1.0,0.0,-0.26555365,0.26398215
Acetylcholine Neurotransmitter Release Cycle,8.266272e-08,11.0,8.266272e-08,-0.2655524,-0.13070862
Acetylcholine regulates insulin secretion,0.023897685,7.0,0.023897685,0.099734075,0.3005511
Acrosome Reaction,0.0,1.0,0.0,-0.26555365,0.26398215
Activated NOTCH1 Transmits Signal to the Nucleus,0.0044236667,22.0,0.0044236667,-0.19793576,-0.5142647
Activated NTRK2 signals through CDK5,0.8939223,6.0,0.8939223,13.398484,10.2929
Activated NTRK2 signals through FRS2 and FRS3,0.010985129,8.0,0.010985129,-0.097640626,0.11336527
Activated NTRK2 signals through FYN,0.13340668,6.0,0.13340668,1.7736324,1.5927777
Activated NTRK2 signals through PI3K,0.7504819,5.0,0.7504819,11.205928,8.691443
Activated NTRK2 signals through PLCG1,0.15648632,3.0,0.15648632,2.126416,1.9752109
Activated NTRK2 signals through RAS,0.02596079,6.0,0.02596079,0.13126963,0.3636217
Activated NTRK3 signals through PI3K,0.082664885,7.0,0.082664885,0.9980193,0.972834
Activated NTRK3 signals through PLCG1,0.04129172,4.0,0.04129172,0.3656104,0.6179423
Activated NTRK3 signals through RAS,0.0008980629,7.0,0.0008980629,-0.25182632,0.037440736
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3,0.001110009,6.0,0.001110009,-0.24858662,0.07933453
Activation and oligomerization of BAK protein,0.00029557862,3.0,0.00029557862,-0.2610356,0.18842517
Activation of AMPA receptors,1.1434564e-07,3.0,1.1434564e-07,-0.26555192,0.1850451
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins,0.002186373,47.0,0.002186373,-0.2321339,-1.5265881
Activation of ATR in response to replication stress,0.002887072,27.0,0.002887072,-0.22142336,-0.7291888
Activation of BAD and translocation to mitochondria ,0.0004170273,12.0,0.0004170273,-0.2591792,-0.16540803
Activation of BIM and translocation to mitochondria ,0.004061652,3.0,0.004061652,-0.20346934,0.23150817
Activation of BMF and translocation to mitochondria,0.0011275272,4.0,0.0011275272,-0.24831885,0.15847328
Activation of C3 and C5,0.0,1.0,0.0,-0.26555365,0.26398215
Activation of DNA fragmentation factor,0.010565123,7.0,0.010565123,-0.10406063,0.14802966
Activation of G protein gated Potassium channels,0.0062443903,16.0,0.0062443903,-0.17010511,-0.256621
Activation of Matrix Metalloproteinases,0.0009033231,15.0,0.0009033231,-0.25174594,-0.27825242
Activation of NF-kappaB in B cells,0.00044797856,48.0,0.00044797856,-0.2587061,-1.5859442
Activation of NOXA and translocation to mitochondria,0.0011962077,4.0,0.0011962077,-0.24726905,0.15925896
Activation of Nicotinic Acetylcholine Receptors,7.614977e-06,10.0,7.614977e-06,-0.26543728,-0.09115328
Activation of PPARGC1A (PGC-1alpha) by phosphorylation,0.00028805126,8.0,0.00028805126,-0.26115066,-0.009006811
Activation of PUMA and translocation to mitochondria,0.009770945,6.0,0.009770945,-0.11620002,0.17841361
Activation of RAC1,4.166483e-06,7.0,4.166483e-06,-0.26548997,0.02721477
Activation of RAS in B cells,0.00084939325,5.0,0.00084939325,-0.25257027,0.11582233
Activation of SMO,2.3137363e-05,7.0,2.3137363e-05,-0.2652,0.027431808
Activation of TRKA receptors,0.5246409,4.0,0.5246409,7.753838,6.1473446
Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.013968847,45.0,0.013968847,-0.052033044,-1.312861
Activation of gene expression by SREBF (SREBP),0.12944347,17.0,0.12944347,1.7130526,1.1132786
Activation of the TFAP2 (AP-2) family of transcription factors,0.005015169,7.0,0.005015169,-0.18889438,0.084539466
"Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S",0.2460737,31.0,0.2460737,3.4958024,1.8949329
Activation of the pre-replicative complex,0.0013387301,23.0,0.0013387301,-0.24509053,-0.58902484
"Activation, myristolyation of BID and translocation to mitochondria",0.019778892,4.0,0.019778892,0.036776327,0.37184057
"Activation, translocation and oligomerization of BAX",0.008171339,3.0,0.008171339,-0.14065078,0.278522
Acyl chain remodeling of CL,0.0008046459,7.0,0.0008046459,-0.25325426,0.03637208
Acyl chain remodeling of DAG and TAG,0.001286064,5.0,0.001286064,-0.24589556,0.12081771
Acyl chain remodelling of PC,0.0012510611,15.0,0.0012510611,-0.24643059,-0.27427438
Acyl chain remodelling of PE,0.008593039,14.0,0.008593039,-0.13420488,-0.1508147
Acyl chain remodelling of PG,0.005202643,10.0,0.005202643,-0.18602872,-0.03172335
Acyl chain remodelling of PI,0.0020929005,10.0,0.0020929005,-0.23356266,-0.06729809
Acyl chain remodelling of PS,0.0048975344,10.0,0.0048975344,-0.19069245,-0.03521373
Adrenaline signalling through Alpha-2 adrenergic receptor,0.00055059296,2.0,0.00055059296,-0.2571376,0.23081161
"Adrenaline,noradrenaline inhibits insulin secretion",0.0587031,22.0,0.0587031,0.6317517,0.10667937
Advanced glycosylation endproduct receptor signaling,0.00010704541,10.0,0.00010704541,-0.26391742,-0.0900158
Aflatoxin activation and detoxification,0.010326356,10.0,0.010326356,-0.107710294,0.02689072
Agmatine biosynthesis,0.005807775,2.0,0.005807775,-0.176779,0.29095256
Alpha-defensins,0.000118624965,4.0,0.000118624965,-0.26374042,0.14693166
Alpha-oxidation of phytanate,0.01162772,6.0,0.01162772,-0.08781831,0.19965471
Alternative complement activation,6.859485e-05,2.0,6.859485e-05,-0.26450515,0.22529769
Amine ligand-binding receptors,0.00158079,20.0,0.00158079,-0.24139053,-0.46784824
Amino acid transport across the plasma membrane,3.8072805e-05,14.0,3.8072805e-05,-0.2649717,-0.24868152
Amplification  of signal from unattached  kinetochores via a MAD2  inhibitory signal,0.011260107,54.0,0.011260107,-0.09343745,-1.6990709
Amyloid fiber formation,0.021993622,34.0,0.021993622,0.07062955,-0.78689855
Anchoring fibril formation,0.0,1.0,0.0,-0.26555365,0.26398215
Anchoring of the basal body to the plasma membrane,0.0006050057,73.0,0.0006050057,-0.25630584,-2.570877
Androgen biosynthesis,0.026126355,5.0,0.026126355,0.13380037,0.4049849
Antagonism of Activin by Follistatin,0.025818093,4.0,0.025818093,0.12908845,0.44092762
"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.00043321037,19.0,0.00043321037,-0.25893185,-0.4415071
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0008968695,22.0,0.0008968695,-0.25184458,-0.55461043
Antigen processing: Ubiquitination & Proteasome degradation,0.0038457103,207.0,1.857831e-05,-0.2652697,-7.822673
Apoptotic cleavage of cell adhesion  proteins,0.0062393844,7.0,0.0062393844,-0.17018163,0.09854422
Arachidonate production from DAG,2.66133e-05,4.0,2.66133e-05,-0.26514685,0.14587909
Aryl hydrocarbon receptor signalling,0.000249424,7.0,0.000249424,-0.2617411,0.030020447
Assembly of active LPL and LIPC lipase complexes,0.02103649,12.0,0.02103649,0.05599933,0.07047383
Assembly of the ORC complex at the origin of replication,9.544912e-06,6.0,9.544912e-06,-0.26540777,0.06674547
Association of TriC/CCT with target proteins during biosynthesis,0.052217703,31.0,0.052217703,0.5326193,-0.32273453
Astrocytic Glutamate-Glutamine Uptake And Metabolism,9.4284536e-05,4.0,9.4284536e-05,-0.26411247,0.14665323
Asymmetric localization of PCP proteins,0.00056508137,43.0,0.00056508137,-0.2569161,-1.3872586
Attachment of GPI anchor to uPAR,0.0002821825,5.0,0.0002821825,-0.26124036,0.109333575
Attenuation phase,0.0021028249,14.0,0.0021028249,-0.23341095,-0.22506122
Autodegradation of Cdh1 by Cdh1:APC/C,0.0062769153,43.0,0.0062769153,-0.16960797,-1.3219166
Axonal growth inhibition (RHOA activation),0.00011913215,5.0,0.00011913215,-0.26373264,0.107468314
Axonal growth stimulation,0.0014366728,4.0,0.0014366728,-0.24359341,0.16200984
B-WICH complex positively regulates rRNA expression,0.0014730211,21.0,0.0014730211,-0.24303782,-0.5085502
BBSome-mediated cargo-targeting to cilium,0.0026791277,12.0,0.0026791277,-0.22460188,-0.13953012
BDNF activates NTRK2 (TRKB) signaling,0.15536563,2.0,0.15536563,2.1092856,2.0018594
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members,1.6387516e-05,5.0,1.6387516e-05,-0.26530316,0.10629293
"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.000834755,7.0,0.000834755,-0.25279403,0.03671653
Basigin interactions,0.072932914,10.0,0.072932914,0.8492614,0.74309516
Beta defensins,5.638789e-06,22.0,5.638789e-06,-0.26546746,-0.5648059
Beta-catenin phosphorylation cascade,0.007184121,12.0,0.007184121,-0.15574089,-0.08799406
Beta-oxidation of pristanoyl-CoA,0.024467308,6.0,0.024467308,0.10844104,0.3465366
Beta-oxidation of very long chain fatty acids,0.0005060903,8.0,0.0005060903,-0.25781783,-0.006512494
Bicarbonate transporters,0.00019725354,6.0,0.00019725354,-0.26253852,0.06889282
Binding of TCF/LEF:CTNNB1 to target gene promoters,9.355913e-05,8.0,9.355913e-05,-0.26412356,-0.011231738
Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB,0.0,1.0,0.0,-0.26555365,0.26398215
"Biosynthesis of A2E, implicated in retinal degradation",0.00049783365,2.0,0.00049783365,-0.25794405,0.23020805
Biosynthesis of D-series resolvins,0.00040729283,4.0,0.00040729283,-0.25932798,0.15023397
Biosynthesis of DHA-derived sulfido conjugates,0.0,1.0,0.0,-0.26555365,0.26398215
Biosynthesis of DPAn-3 SPMs,0.005919969,3.0,0.005919969,-0.17506406,0.25276688
Biosynthesis of DPAn-6 SPMs,0.0003943607,2.0,0.0003943607,-0.25952566,0.22902437
Biosynthesis of E-series 18(R)-resolvins,0.0077957353,4.0,0.0077957353,-0.14639206,0.23475602
Biosynthesis of E-series 18(S)-resolvins,0.002296379,4.0,0.002296379,-0.23045239,0.17184466
Biosynthesis of aspirin-triggered D-series resolvins,0.002156382,4.0,0.002156382,-0.23259231,0.17024314
Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives,0.0056616985,2.0,0.0056616985,-0.17901185,0.28928146
Biosynthesis of maresins,0.0005215609,4.0,0.0005215609,-0.25758135,0.15154116
Biosynthesis of protectins,4.6437071e-07,3.0,4.6437071e-07,-0.26554656,0.18504912
Biotin transport and metabolism,0.1466457,11.0,0.1466457,1.975997,1.546883
Breakdown of the nuclear lamina,0.0022931355,3.0,0.0022931355,-0.23050196,0.21127675
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,0.047196615,13.0,0.047196615,0.45586956,0.3302704
Butyrophilin (BTN) family interactions,0.003614229,9.0,0.003614229,-0.21030842,-0.010425288
C6 deamination of adenosine,0.0007113169,2.0,0.0007113169,-0.25468084,0.23265027
CASP8 activity is inhibited,0.00050900504,9.0,0.00050900504,-0.25777328,-0.045948327
CD209 (DC-SIGN) signaling,0.0011872111,16.0,0.0011872111,-0.24740657,-0.31447396
CD22 mediated BCR regulation,0.0009905028,5.0,0.0009905028,-0.25041336,0.117436565
CD28 dependent PI3K/Akt signaling,0.0029198872,15.0,0.0029198872,-0.22092177,-0.2551834
CD28 dependent Vav1 pathway,0.0026400134,9.0,0.0026400134,-0.22519977,-0.021570083
CDC6 association with the ORC:origin complex,4.9047617e-06,7.0,4.9047617e-06,-0.2654787,0.027223209
CDK-mediated phosphorylation and removal of Cdc6,0.11503135,48.0,0.11503135,1.4927564,-0.27513695
CDO in myogenesis,0.019731613,23.0,0.019731613,0.036053635,-0.37861454
CDT1 association with the CDC6:ORC:origin complex,3.0517826e-05,38.0,3.0517826e-05,-0.2650872,-1.196028
CHL1 interactions,0.0009358164,5.0,0.0009358164,-0.25124925,0.11681099
CLEC7A (Dectin-1) induces NFAT activation,0.0013844622,8.0,0.0013844622,-0.24439147,0.0035359017
CLEC7A/inflammasome pathway,0.00015964039,3.0,0.00015964039,-0.2631135,0.18687005
COPI-dependent Golgi-to-ER retrograde traffic,3.1860283e-05,49.0,3.1860283e-05,-0.26506665,-1.6301737
COPI-independent Golgi-to-ER retrograde traffic,6.228721e-05,27.0,6.228721e-05,-0.2646016,-0.7615037
COPI-mediated anterograde transport,0.00034298943,63.0,0.00034298943,-0.2603109,-2.1791828
COPII-mediated vesicle transport,0.00033222925,54.0,0.00033222925,-0.26047537,-1.8240834
COX reactions,0.0,2.0,0.0,-0.26555365,0.22451296
CREB3 factors activate genes,0.013730302,9.0,0.013730302,-0.05567931,0.10530024
CRMPs in Sema3A signaling,0.000519288,11.0,0.000519288,-0.25761607,-0.12476901
CS/DS degradation,0.014038377,8.0,0.014038377,-0.050970234,0.14829373
CTLA4 inhibitory signaling,0.0014869515,16.0,0.0014869515,-0.24282488,-0.311045
Ca2+ activated K+ channels,0.0003395394,4.0,0.0003395394,-0.26036364,0.14945889
Ca2+ pathway,0.002861862,43.0,0.002861862,-0.2218087,-1.3609838
Calcineurin activates NFAT,1.9665285e-05,8.0,1.9665285e-05,-0.26525307,-0.012077077
Calcitonin-like ligand receptors,0.015157348,3.0,0.015157348,-0.033866234,0.35844034
Calmodulin induced events,0.007203811,13.0,0.007203811,-0.15543991,-0.12723798
Calnexin/calreticulin cycle,0.010391438,21.0,0.010391438,-0.10671547,-0.40652564
Carboxyterminal post-translational modifications of tubulin,0.0025940584,21.0,0.0025940584,-0.22590221,-0.49572584
Cargo concentration in the ER,0.00021940221,20.0,0.00021940221,-0.26219997,-0.4834222
Cargo recognition for clathrin-mediated endocytosis,0.00070994365,65.0,0.00070994365,-0.25470182,-2.2539232
Carnitine synthesis,0.0022959283,5.0,0.0022959283,-0.23045929,0.13237034
Caspase-mediated cleavage of cytoskeletal proteins,0.0044456646,11.0,0.0044456646,-0.19759952,-0.079852186
Catecholamine biosynthesis,0.0019456696,4.0,0.0019456696,-0.23581316,0.16783264
Cation-coupled Chloride cotransporters,0.00021500945,3.0,0.00021500945,-0.26226714,0.18750346
Cell redox homeostasis,0.0,1.0,0.0,-0.26555365,0.26398215
Cellular hexose transport,0.004759069,9.0,0.004759069,-0.19280897,0.0026714187
Centrosome maturation,0.022119623,57.0,0.022119623,0.07255553,-1.693248
Ceramide signalling,0.0030050187,2.0,0.0030050187,-0.2196205,0.25888968
ChREBP activates metabolic gene expression,2.636774e-05,5.0,2.636774e-05,-0.2651506,0.1064071
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex,0.0005583274,7.0,0.0005583274,-0.25701934,0.03355426
Cholesterol biosynthesis via desmosterol,0.0047345627,2.0,0.0047345627,-0.19318357,0.27867526
Cholesterol biosynthesis via lathosterol,0.03008637,2.0,0.03008637,0.19433114,0.568694
Choline catabolism,0.0110795945,3.0,0.0110795945,-0.096196674,0.31179178
Chondroitin sulfate biosynthesis,0.0028863556,12.0,0.0028863556,-0.22143431,-0.1371595
Chylomicron assembly,7.5849186e-07,5.0,7.5849186e-07,-0.26554206,0.106114134
Chylomicron clearance,2.3775506e-07,2.0,2.3775506e-07,-0.26555002,0.22451568
Chylomicron remodeling,0.004856119,6.0,0.004856119,-0.19132552,0.12218916
Citric acid cycle (TCA cycle),0.066751756,19.0,0.066751756,0.7547794,0.31716162
Class C/3 (Metabotropic glutamate/pheromone receptors),0.0062314365,18.0,0.0062314365,-0.17030312,-0.33570755
Classical Kir channels,0.0032796215,3.0,0.0032796215,-0.21542305,0.22256193
Cleavage of Growing Transcript in the Termination Region ,0.019908097,53.0,0.019908097,0.038751278,-1.5606709
Cleavage of the damaged purine,2.1947677e-07,3.0,2.1947677e-07,-0.26555032,0.18504632
Cleavage of the damaged pyrimidine ,0.00366205,8.0,0.00366205,-0.20957746,0.029590957
"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.06022823,14.0,0.06022823,0.6550641,0.43987983
Coenzyme A biosynthesis,0.0042559947,4.0,0.0042559947,-0.2004987,0.19426222
Cohesin Loading onto Chromatin,0.015913546,9.0,0.015913546,-0.022307372,0.13027604
Collagen chain trimerization,0.005300566,21.0,0.005300566,-0.18453193,-0.46476403
Collagen degradation,0.008884707,15.0,0.008884707,-0.1297466,-0.18694726
Common Pathway of Fibrin Clot Formation,0.019508878,13.0,0.019508878,0.03264902,0.013529125
Complex I biogenesis,0.025823977,25.0,0.025823977,0.12917839,-0.38785762
Condensation of Prometaphase Chromosomes,0.0015602073,5.0,0.0015602073,-0.24170513,0.123953864
Condensation of Prophase Chromosomes,0.00014829994,7.0,0.00014829994,-0.26328683,0.028863635
Conjugation of carboxylic acids,6.7257497e-07,5.0,6.7257497e-07,-0.26554337,0.10611315
Constitutive Signaling by AKT1 E17K in Cancer,0.0015842554,22.0,0.0015842554,-0.24133754,-0.5467469
Constitutive Signaling by Aberrant PI3K in Cancer,0.04363798,46.0,0.04363798,0.4014741,-1.0129223
Constitutive Signaling by EGFRvIII,0.013987043,13.0,0.013987043,-0.051754907,-0.04963938
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants,0.0013031,16.0,0.0013031,-0.24563515,-0.31314823
Constitutive Signaling by NOTCH1 HD Domain Mutants,0.0010975512,11.0,0.0010975512,-0.24877706,-0.11815383
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,0.001890516,41.0,0.001890516,-0.2366562,-1.2931576
Constitutive Signaling by NOTCH1 PEST Domain Mutants,0.0019834868,41.0,0.0019834868,-0.2352351,-1.292094
Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,0.003544045,5.0,0.003544045,-0.21138121,0.1466485
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase,0.012380031,14.0,0.012380031,-0.07631887,-0.107492395
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding,0.09009265,26.0,0.09009265,1.1115563,0.3078918
Creatine metabolism,0.32309735,7.0,0.32309735,4.6731462,3.7233255
Creation of C4 and C2 activators,0.00012316095,5.0,0.00012316095,-0.26367107,0.1075144
Cristae formation,0.0035442382,9.0,0.0035442382,-0.21137825,-0.0112259565
Cross-presentation of particulate exogenous antigens (phagosomes),3.6924597e-05,4.0,3.6924597e-05,-0.26498926,0.14599705
Cross-presentation of soluble exogenous antigens (endosomes),4.548154e-05,30.0,4.548154e-05,-0.26485845,-0.88010347
Crosslinking of collagen fibrils,8.674535e-06,4.0,8.674535e-06,-0.26542106,0.14567386
Cyclin A/B1/B2 associated events during G2/M transition,0.0026978971,13.0,0.0026978971,-0.22431499,-0.17878458
Cyclin D associated events in G1,0.04719951,33.0,0.04719951,0.4559138,-0.4590799
Cysteine formation from homocysteine,0.0001457051,3.0,0.0001457051,-0.2633265,0.18671063
Cytochrome c-mediated apoptotic response,0.0030932103,6.0,0.0030932103,-0.21827245,0.10202189
Cytosolic iron-sulfur cluster assembly,0.0059983316,10.0,0.0059983316,-0.17386624,-0.022620864
Cytosolic tRNA aminoacylation,0.06289207,7.0,0.06289207,0.69578224,0.74663776
DAP12 signaling,0.0005460516,21.0,0.0005460516,-0.257207,-0.51915455
DCC mediated attractive signaling,0.0025439125,13.0,0.0025439125,-0.22666873,-0.18054612
DEx/H-box helicases activate type I IFN and inflammatory cytokines production ,0.0027853264,7.0,0.0027853264,-0.22297859,0.0590306
DNA Damage Recognition in GG-NER,0.00091855467,21.0,0.00091855467,-0.25151312,-0.5148932
DNA methylation,0.015808566,4.0,0.015808566,-0.02391205,0.32642093
DNA replication initiation,9.834747e-05,6.0,9.834747e-05,-0.26405036,0.06776135
DSCAM interactions,0.00034522437,9.0,0.00034522437,-0.26027673,-0.04782193
Deactivation of the beta-catenin transactivating complex,0.0022648044,30.0,0.0022648044,-0.23093502,-0.85471493
Deadenylation of mRNA,0.7466165,17.0,0.7466165,11.146843,8.1735935
Dectin-1 mediated noncanonical NF-kB signaling,0.0038275307,38.0,0.0038275307,-0.20704798,-1.1525911
Dectin-2 family,0.00044448956,12.0,0.00044448956,-0.2587594,-0.16509385
Defective ABCA1 causes Tangier disease,0.0,1.0,0.0,-0.26555365,0.26398215
Defective ABCA12 causes autosomal recessive congenital ichthyosis type 4B,0.0,1.0,0.0,-0.26555365,0.26398215
Defective ABCA3 causes pulmonary surfactant metabolism dysfunction 3 (SMDP3),0.0,1.0,0.0,-0.26555365,0.26398215
Defective ABCA3 causes pulmonary surfactant metabolism dysfunction type 3 (SMDP3),0.0,1.0,0.0,-0.26555365,0.26398215
Defective ABCB11 causes progressive familial intrahepatic cholestasis 2 and benign recurrent intrahepatic cholestasis 2,0.0,1.0,0.0,-0.26555365,0.26398215
"Defective ABCB4 causes progressive familial intrahepatic cholestasis 3, intrahepatic cholestasis of pregnancy 3 and gallbladder disease 1",0.0,1.0,0.0,-0.26555365,0.26398215
Defective ABCB6 causes isolated colobomatous microphthalmia 7 (MCOPCB7),0.0,1.0,0.0,-0.26555365,0.26398215
Defective ABCC2 causes Dubin-Johnson syndrome,0.0,1.0,0.0,-0.26555365,0.26398215
Defective ABCC6 causes pseudoxanthoma elasticum (PXE),0.0,1.0,0.0,-0.26555365,0.26398215
Defective ABCC8 can cause hypoglycemias and hyperglycemias,2.6115427e-05,2.0,2.6115427e-05,-0.26515445,0.22481173
"Defective ABCC9 causes dilated cardiomyopathy 10, familial atrial fibrillation 12 and hypertrichotic osteochondrodysplasia",0.0,1.0,0.0,-0.26555365,0.26398215
Defective ABCD1 causes adrenoleukodystrophy (ALD),0.0,1.0,0.0,-0.26555365,0.26398215
"Defective ABCD4 causes methylmalonic aciduria and homocystinuria, cblj type (MAHCJ)",0.0,2.0,0.0,-0.26555365,0.22451296
Defective ABCG5 causes sitosterolemia,0.0,1.0,0.0,-0.26555365,0.26398215
Defective ABCG8 causes gallbladder disease 4 and sitosterolemia,0.0,1.0,0.0,-0.26555365,0.26398215
Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD),0.00041322317,3.0,0.00041322317,-0.25923732,0.189771
Defective ACY1 causes encephalopathy,0.0,1.0,0.0,-0.26555365,0.26398215
Defective AHCY causes Hypermethioninemia with S-adenosylhomocysteine hydrolase deficiency (HMAHCHD),0.0,1.0,0.0,-0.26555365,0.26398215
Defective ALG1 causes ALG1-CDG (CDG-1k),0.0,1.0,0.0,-0.26555365,0.26398215
Defective ALG11 causes ALG11-CDG (CDG-1p),0.0,1.0,0.0,-0.26555365,0.26398215
Defective ALG12 causes ALG12-CDG (CDG-1g),0.0,1.0,0.0,-0.26555365,0.26398215
Defective ALG14 causes congenital myasthenic syndrome (ALG14-CMS),0.0,1.0,0.0,-0.26555365,0.26398215
Defective ALG2 causes ALG2-CDG (CDG-1i),0.0,1.0,0.0,-0.26555365,0.26398215
Defective ALG3 causes ALG3-CDG (CDG-1d),0.0,1.0,0.0,-0.26555365,0.26398215
Defective ALG6 causes ALG6-CDG (CDG-1c),0.0,1.0,0.0,-0.26555365,0.26398215
Defective ALG8 causes ALG8-CDG (CDG-1h),0.0,1.0,0.0,-0.26555365,0.26398215
Defective ALG9 causes ALG9-CDG (CDG-1l),0.0,1.0,0.0,-0.26555365,0.26398215
Defective AMN causes hereditary megaloblastic anemia 1,0.0,1.0,0.0,-0.26555365,0.26398215
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),0.004889911,3.0,0.004889911,-0.190809,0.24098326
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),0.004889911,2.0,0.004889911,-0.190809,0.2804524
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),3.880637e-07,3.0,3.880637e-07,-0.26554775,0.18504824
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),3.880637e-07,2.0,3.880637e-07,-0.26554775,0.2245174
Defective B3GALT6 causes EDSP2 and SEMDJL1,0.00604302,9.0,0.00604302,-0.17318316,0.017359529
Defective B3GALTL causes Peters-plus syndrome (PpS),0.010093632,11.0,0.010093632,-0.11126759,-0.015240756
Defective B3GAT3 causes JDSSDHD,0.018855631,9.0,0.018855631,0.022663834,0.1639328
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.00038994174,3.0,0.00038994174,-0.25959322,0.18950465
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.00038994174,1.0,0.00038994174,-0.25959322,0.268443
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,3.0,0.0,-0.26555365,0.1850438
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,1.0,0.0,-0.26555365,0.26398215
"Defective B4GALT7 causes EDS, progeroid type",0.0051216516,9.0,0.0051216516,-0.18726672,0.0068192785
Defective BTD causes biotidinase deficiency,0.0,1.0,0.0,-0.26555365,0.26398215
Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS),3.2536285e-05,7.0,3.2536285e-05,-0.2650563,0.027539324
Defective CD320 causes methylmalonic aciduria,0.0028719243,3.0,0.0028719243,-0.2216549,0.21789794
Defective CFTR causes cystic fibrosis,0.06352443,40.0,0.06352443,0.70544815,-0.54861075
"Defective CHST14 causes EDS, musculocontractural type",1.2182502e-07,2.0,1.2182502e-07,-0.2655518,0.22451434
Defective CHST3 causes SEDCJD,5.5959547e-12,2.0,5.5959547e-12,-0.26555365,0.22451296
Defective CHST6 causes MCDC1,0.0019351407,3.0,0.0019351407,-0.23597409,0.20718136
Defective CHSY1 causes TPBS,3.9200734e-07,2.0,3.9200734e-07,-0.2655477,0.22451745
Defective CP causes aceruloplasminemia (ACERULOP),0.0,1.0,0.0,-0.26555365,0.26398215
Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4),0.00035482907,3.0,0.00035482907,-0.26012993,0.18910296
Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5),0.015835196,3.0,0.015835196,-0.023504993,0.36619475
Defective CUBN causes hereditary megaloblastic anemia 1,0.0,1.0,0.0,-0.26555365,0.26398215
"Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)",0.0012448491,3.0,0.0012448491,-0.24652554,0.19928458
Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4),0.0,1.0,0.0,-0.26555365,0.26398215
Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency),0.0,1.0,0.0,-0.26555365,0.26398215
Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5),0.0,1.0,0.0,-0.26555365,0.26398215
Defective CYP19A1 causes Aromatase excess syndrome (AEXS),0.0,1.0,0.0,-0.26555365,0.26398215
Defective CYP1B1 causes Glaucoma,0.0,1.0,0.0,-0.26555365,0.26398215
Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3),0.0,1.0,0.0,-0.26555365,0.26398215
"Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)",0.0,1.0,0.0,-0.26555365,0.26398215
Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA),0.0,1.0,0.0,-0.26555365,0.26398215
Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4),0.0,1.0,0.0,-0.26555365,0.26398215
Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX),0.0,1.0,0.0,-0.26555365,0.26398215
Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A),0.0,1.0,0.0,-0.26555365,0.26398215
Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B),0.0,1.0,0.0,-0.26555365,0.26398215
"Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)",0.0,1.0,0.0,-0.26555365,0.26398215
"Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)",0.0,1.0,0.0,-0.26555365,0.26398215
"Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)",0.0,1.0,0.0,-0.26555365,0.26398215
Defective DHDDS causes retinitis pigmentosa 59,0.0,1.0,0.0,-0.26555365,0.26398215
Defective DOLK causes DOLK-CDG (CDG-1m),0.0,1.0,0.0,-0.26555365,0.26398215
Defective DPAGT1 causes DPAGT1-CDG (CDG-1j) and CMSTA2,0.0,1.0,0.0,-0.26555365,0.26398215
Defective DPM1 causes DPM1-CDG (CDG-1e),0.0,1.0,0.0,-0.26555365,0.26398215
Defective DPM2 causes DPM2-CDG (CDG-1u),0.0,1.0,0.0,-0.26555365,0.26398215
Defective DPM3 causes DPM3-CDG (CDG-1o),0.0,1.0,0.0,-0.26555365,0.26398215
"Defective EXT1 causes exostoses 1, TRPS2 and CHDS",0.0013428052,8.0,0.0013428052,-0.24502823,0.0030593404
Defective EXT2 causes exostoses 2,0.008545694,8.0,0.008545694,-0.13492857,0.08545871
Defective FMO3 causes Trimethylaminuria (TMAU),0.0,1.0,0.0,-0.26555365,0.26398215
Defective GALE can cause Epimerase-deficiency galactosemia (EDG),0.0,1.0,0.0,-0.26555365,0.26398215
Defective GALK1 can cause Galactosemia II (GALCT2),0.0,1.0,0.0,-0.26555365,0.26398215
Defective GALNT12 causes colorectal cancer 1 (CRCS1),2.6614403e-05,7.0,2.6614403e-05,-0.26514685,0.027471568
Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC),0.00072643306,7.0,0.00072643306,-0.25444978,0.035477336
Defective GALT can cause Galactosemia,0.0,1.0,0.0,-0.26555365,0.26398215
Defective GCK causes maturity-onset diabetes of the young 2 (MODY2),0.0,1.0,0.0,-0.26555365,0.26398215
Defective GCLC causes Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency (HAGGSD),0.0,1.0,0.0,-0.26555365,0.26398215
Defective GFPT1 causes CMSTA1,0.0,1.0,0.0,-0.26555365,0.26398215
Defective GGT1 causes Glutathionuria (GLUTH),0.0,1.0,0.0,-0.26555365,0.26398215
Defective GGT1 causes Glutathionuria (GLUTH),0.0,1.0,0.0,-0.26555365,0.26398215
Defective GGT1 causes Glutathionuria (GLUTH),0.0,1.0,0.0,-0.26555365,0.26398215
Defective GGT1 causes Glutathionuria (GLUTH),0.0,1.0,0.0,-0.26555365,0.26398215
Defective GIF causes intrinsic factor deficiency,0.0,1.0,0.0,-0.26555365,0.26398215
"Defective GNE causes sialuria, Nonaka myopathy and inclusion body myopathy 2",0.0,1.0,0.0,-0.26555365,0.26398215
Defective GSS causes Glutathione synthetase deficiency (GSS deficiency),0.0,1.0,0.0,-0.26555365,0.26398215
Defective HEXA causes GM2G1,0.0,1.0,0.0,-0.26555365,0.26398215
Defective HEXB causes GM2G2,0.0,1.0,0.0,-0.26555365,0.26398215
Defective HK1 causes hexokinase deficiency (HK deficiency),0.0,1.0,0.0,-0.26555365,0.26398215
Defective HLCS causes multiple carboxylase deficiency,0.005659463,6.0,0.005659463,-0.17904602,0.13137922
Defective LARGE causes MDDGA6 and MDDGB6,0.0,1.0,0.0,-0.26555365,0.26398215
Defective LFNG causes SCDO3,0.0013925021,4.0,0.0013925021,-0.24426858,0.16150454
Defective LMBRD1 causes methylmalonic aciduria and homocystinuria type cblF,0.0,1.0,0.0,-0.26555365,0.26398215
Defective MAN1B1 causes MRT15,0.0,1.0,0.0,-0.26555365,0.26398215
Defective MAOA causes Brunner syndrome (BRUNS),0.0,1.0,0.0,-0.26555365,0.26398215
Defective MAT1A causes Methionine adenosyltransferase deficiency (MATD),0.0,1.0,0.0,-0.26555365,0.26398215
Defective MGAT2 causes MGAT2-CDG (CDG-2a),0.0,1.0,0.0,-0.26555365,0.26398215
Defective MMAA causes methylmalonic aciduria type cblA,0.00027061187,2.0,0.00027061187,-0.2614172,0.2276087
Defective MMAB causes methylmalonic aciduria type cblB,0.0,1.0,0.0,-0.26555365,0.26398215
Defective MMACHC causes methylmalonic aciduria and homocystinuria type cblC,5.259253e-05,2.0,5.259253e-05,-0.26474977,0.2251146
Defective MMADHC causes methylmalonic aciduria and homocystinuria type cblD,0.004005803,3.0,0.004005803,-0.20432302,0.23086926
Defective MOGS causes MOGS-CDG (CDG-2b),0.0,1.0,0.0,-0.26555365,0.26398215
Defective MPDU1 causes MPDU1-CDG (CDG-1f),0.0,1.0,0.0,-0.26555365,0.26398215
Defective MPI causes MPI-CDG (CDG-1b),0.0,1.0,0.0,-0.26555365,0.26398215
Defective MTR causes methylmalonic aciduria and homocystinuria type cblG,0.007004635,3.0,0.007004635,-0.1584844,0.26517522
Defective MTRR causes methylmalonic aciduria and homocystinuria type cblE,5.6776025e-05,3.0,5.6776025e-05,-0.2646858,0.18569331
Defective MUT causes methylmalonic aciduria mut type,0.0,1.0,0.0,-0.26555365,0.26398215
Defective Mismatch Repair Associated With MLH1,0.0016109751,3.0,0.0016109751,-0.24092911,0.203473
Defective Mismatch Repair Associated With MSH2,0.00021402848,3.0,0.00021402848,-0.26228213,0.18749225
Defective Mismatch Repair Associated With MSH3,0.00015948829,2.0,0.00015948829,-0.2631158,0.22633748
Defective Mismatch Repair Associated With MSH6,0.0021485907,2.0,0.0021485907,-0.2327114,0.24909233
Defective Mismatch Repair Associated With PMS2,0.0049957237,3.0,0.0049957237,-0.1891916,0.24219374
Defective NEU1 causes sialidosis,0.0,1.0,0.0,-0.26555365,0.26398215
Defective OPLAH causes 5-oxoprolinase deficiency (OPLAHD),0.0,1.0,0.0,-0.26555365,0.26398215
Defective PAPSS2 causes SEMD-PA,0.0,1.0,0.0,-0.26555365,0.26398215
Defective PGM1 causes PGM1-CDG (CDG1t),0.0,1.0,0.0,-0.26555365,0.26398215
Defective PMM2 causes PMM2-CDG (CDG-1a),0.0,1.0,0.0,-0.26555365,0.26398215
"Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3",0.0004999122,2.0,0.0004999122,-0.25791228,0.23023182
"Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1",0.00024141755,2.0,0.00024141755,-0.26186347,0.22727472
"Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2",0.0029191277,2.0,0.0029191277,-0.22093336,0.25790712
Defective RFT1 causes RFT1-CDG (CDG-1n),0.0,1.0,0.0,-0.26555365,0.26398215
Defective RHAG causes regulator type Rh-null hemolytic anemia (RHN),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SFTPA2 causes idiopathic pulmonary fibrosis (IPF),0.0,1.0,0.0,-0.26555365,0.26398215
"Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1)",0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC12A1 causes Bartter syndrome 1 (BS1),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC12A3 causes Gitelman syndrome (GS),0.0,1.0,0.0,-0.26555365,0.26398215
"Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN)",0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC17A5 causes Salla disease (SD) and ISSD,0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC17A8 causes autosomal dominant deafness 25 (DFNA25),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC1A3 causes episodic ataxia 6 (EA6),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC22A12 causes renal hypouricemia 1 (RHUC1),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC22A18 causes lung cancer (LNCR) and embryonal rhabdomyosarcoma 1 (RMSE1),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC22A5 causes systemic primary carnitine deficiency (CDSP),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC24A1 causes congenital stationary night blindness 1D (CSNB1D),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC24A4 causes hypomineralized amelogenesis imperfecta (AI),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC24A5 causes oculocutaneous albinism 6 (OCA6),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC26A2 causes chondrodysplasias,0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC26A3 causes congenital secretory chloride diarrhea 1 (DIAR1),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC26A4 causes Pendred syndrome (PDS),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC27A4 causes ichthyosis prematurity syndrome (IPS),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC29A3 causes histiocytosis-lymphadenopathy plus syndrome (HLAS),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC2A10 causes arterial tortuosity syndrome (ATS),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC2A2 causes Fanconi-Bickel syndrome (FBS),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC2A9 causes hypouricemia renal 2 (RHUC2),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC33A1 causes spastic paraplegia 42 (SPG42),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC34A1 causes hypophosphatemic nephrolithiasis/osteoporosis 1 (NPHLOP1),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC34A3 causes Hereditary hypophosphatemic rickets with hypercalciuria (HHRH),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC35A2 causes congenital disorder of glycosylation 2M (CDG2M),0.0,1.0,0.0,-0.26555365,0.26398215
"Defective SLC35A3 causes arthrogryposis, mental retardation, and seizures (AMRS)",0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC35C1 causes congenital disorder of glycosylation 2C (CDG2C),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC35D1 causes Schneckenbecken dysplasia (SCHBCKD),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC36A2 causes iminoglycinuria (IG) and hyperglycinuria (HG),0.0,1.0,0.0,-0.26555365,0.26398215
"Defective SLC39A4 causes acrodermatitis enteropathica, zinc-deficiency type (AEZ)",0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC3A1 causes cystinuria (CSNU),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC40A1 causes hemochromatosis 4 (HFE4) (duodenum),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.0,1.0,0.0,-0.26555365,0.26398215
"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",0.0,1.0,0.0,-0.26555365,0.26398215
"Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA)",0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC5A1 causes congenital glucose/galactose malabsorption (GGM),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC5A2 causes renal glucosuria (GLYS1),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC5A5 causes thyroid dyshormonogenesis 1 (TDH1),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC6A2 causes orthostatic intolerance (OI),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC6A5 causes hyperekplexia 3 (HKPX3),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC7A7 causes lysinuric protein intolerance (LPI),0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC7A9 causes cystinuria (CSNU),0.0,1.0,0.0,-0.26555365,0.26398215
"Defective SLC9A6 causes  X-linked, syndromic mental retardation,, Christianson type (MRXSCH)",0.0,1.0,0.0,-0.26555365,0.26398215
Defective SLC9A9 causes autism 16 (AUTS16),0.0,1.0,0.0,-0.26555365,0.26398215
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",4.2475494e-06,2.0,4.2475494e-06,-0.26548874,0.22456154
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",4.2475494e-06,1.0,4.2475494e-06,-0.26548874,0.26403072
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",0.0,2.0,0.0,-0.26555365,0.22451296
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",0.0,1.0,0.0,-0.26555365,0.26398215
"Defective SLCO1B3 causes hyperbilirubinemia, Rotor type (HBLRR)",2.6601495e-07,2.0,2.6601495e-07,-0.2655496,0.22451602
"Defective SLCO2A1 causes primary, autosomal recessive hypertrophic osteoarthropathy 2 (PHOAR2)",0.0,1.0,0.0,-0.26555365,0.26398215
Defective SRD5A3 causes SRD5A3-CDG (CDG-1q) and KHRZ,0.0,1.0,0.0,-0.26555365,0.26398215
Defective ST3GAL3 causes MCT12 and EIEE15,0.0030798463,3.0,0.0030798463,-0.21847671,0.22027652
Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD),0.0,1.0,0.0,-0.26555365,0.26398215
Defective TCN2 causes hereditary megaloblastic anemia,0.007326336,2.0,0.007326336,-0.15356705,0.30832455
Defective TPMT causes Thiopurine S-methyltransferase deficiency (TPMT deficiency),0.0,1.0,0.0,-0.26555365,0.26398215
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC),3.5087505e-05,2.0,3.5087505e-05,-0.26501733,0.22491436
Defective UGT1A1 causes hyperbilirubinemia,0.0,1.0,0.0,-0.26555365,0.26398215
Defective UGT1A4 causes hyperbilirubinemia,0.0,1.0,0.0,-0.26555365,0.26398215
Defective pro-SFTPB causes pulmonary surfactant metabolism dysfunction 1 (SMDP1) and respiratory distress syndrome (RDS),0.048988655,4.0,0.048988655,0.48326176,0.7059934
Defective pro-SFTPC causes pulmonary surfactant metabolism dysfunction 2 (SMDP2) and respiratory distress syndrome (RDS),0.0008057934,2.0,0.0008057934,-0.2532367,0.23373103
Degradation of AXIN,0.00034081598,38.0,0.00034081598,-0.26034412,-1.1924783
Degradation of DVL,0.0088712,38.0,0.0088712,-0.12995306,-1.0948927
Degradation of GABA,0.000121610974,2.0,0.000121610974,-0.2636948,0.22590415
Degradation of GLI1 by the proteasome,0.00022719236,40.0,0.00022719236,-0.2620809,-1.2727164
Degradation of GLI2 by the proteasome,0.0036652859,39.0,0.0036652859,-0.20952798,-1.1939163
Deletions in the AMER1 gene destabilize the destruction complex,2.1598511e-05,2.0,2.1598511e-05,-0.2652235,0.22476004
Deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling,6.833111e-05,2.0,6.833111e-05,-0.2645092,0.22529465
Deposition of new CENPA-containing nucleosomes at the centromere,0.016912725,16.0,0.016912725,-0.0070344377,-0.13457777
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,0.083552085,16.0,0.083552085,1.0115806,0.6277609
Dermatan sulfate biosynthesis,1.8373234e-05,4.0,1.8373234e-05,-0.26527283,0.14578481
Detoxification of Reactive Oxygen Species,0.0010647849,16.0,0.0010647849,-0.2492779,-0.3158745
Digestion of dietary carbohydrate,0.011384331,7.0,0.011384331,-0.09153863,0.1574012
Digestion of dietary lipid,0.0008416198,7.0,0.0008416198,-0.2526891,0.036795042
Dimerization of procaspase-8,0.007420322,8.0,0.007420322,-0.15213042,0.07258471
Disassembly of the destruction complex and recruitment of AXIN to the membrane,0.00063117035,23.0,0.00063117035,-0.25590593,-0.59711915
Disinhibition of SNARE formation,0.04754333,3.0,0.04754333,0.46116924,0.7289284
Displacement of DNA glycosylase by APEX1,0.026130522,9.0,0.026130522,0.13386407,0.24715586
Dissolution of Fibrin Clot,0.0011892963,5.0,0.0011892963,-0.24737468,0.11971074
Dopamine Neurotransmitter Release Cycle,7.4967946e-05,11.0,7.4967946e-05,-0.26440775,-0.12985194
Downregulation of ERBB2:ERBB3 signaling,0.00040185906,12.0,0.00040185906,-0.25941107,-0.16558155
Downregulation of ERBB4 signaling,0.00030252774,8.0,0.00030252774,-0.26092938,-0.008841208
Downregulation of SMAD2/3:SMAD4 transcriptional activity,0.0063699326,19.0,0.0063699326,-0.16818614,-0.37359235
Downregulation of TGF-beta receptor signaling,0.00076596515,21.0,0.00076596515,-0.2538455,-0.51663876
Downstream TCR signaling,0.008108702,58.0,0.008108702,-0.14160821,-1.8929988
Downstream signal transduction,0.00030195503,25.0,0.00030195503,-0.26093814,-0.6798236
Downstream signaling of activated FGFR1,0.17390361,22.0,0.17390361,2.3926475,1.4245465
Downstream signaling of activated FGFR2,0.06422639,21.0,0.06422639,0.71617794,0.2093337
Downstream signaling of activated FGFR3,0.18179709,19.0,0.18179709,2.513303,1.6332536
Downstream signaling of activated FGFR4,0.018969811,22.0,0.018969811,0.024409132,-0.3478602
Dual Incision in GG-NER,0.050466117,33.0,0.050466117,0.5058455,-0.42171067
Dual incision in TC-NER,0.039379403,51.0,0.039379403,0.33637968,-1.258985
E2F mediated regulation of DNA replication,0.008579147,15.0,0.008579147,-0.13441722,-0.19044277
E3 ubiquitin ligases ubiquitinate target proteins,0.008962581,32.0,0.008962581,-0.12855625,-0.85703224
ECM proteoglycans,0.13902552,24.0,0.13902552,1.8595191,0.9466109
EGFR downregulation,0.036202125,18.0,0.036202125,0.28781343,0.00715015
EGFR interacts with phospholipase C-gamma,0.0066755,3.0,0.0066755,-0.16351539,0.26140997
EPH-ephrin mediated repulsion of cells,0.0011476557,33.0,0.0011476557,-0.24801119,-0.9859024
EPHA-mediated growth cone collapse,0.00029722412,12.0,0.00029722412,-0.26101044,-0.16677855
EPHB-mediated forward signaling,2.9435532e-05,29.0,2.9435532e-05,-0.26510373,-0.84081787
ER-Phagosome pathway,1.3447702e-05,48.0,1.3447702e-05,-0.2653481,-1.590915
ERBB2 Activates PTK6 Signaling,0.0072370344,9.0,0.0072370344,-0.15493208,0.031018754
ERBB2 Regulates Cell Motility,0.11755414,10.0,0.11755414,1.5313185,1.2535517
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.014920761,12.0,0.014920761,-0.037482575,0.00051130203
Early Phase of HIV Life Cycle,0.00017678962,8.0,0.00017678962,-0.26285136,-0.01027962
Eicosanoid ligand-binding receptors,0.0064341826,3.0,0.0064341826,-0.16720405,0.25864935
Eicosanoids,0.0018014443,7.0,0.0018014443,-0.23801771,0.047775205
Electric Transmission Across Gap Junctions,0.0028490631,4.0,0.0028490631,-0.22200435,0.17816724
Electron transport from NADPH to Ferredoxin,0.008655478,3.0,0.008655478,-0.13325046,0.28406045
Elevation of cytosolic Ca2+ levels,0.002273169,5.0,0.002273169,-0.23080716,0.13210998
Endogenous sterols,0.0029469475,12.0,0.0029469475,-0.22050813,-0.13646634
Endosomal Sorting Complex Required For Transport (ESCRT),0.0005296576,24.0,0.0005296576,-0.25745758,-0.63774955
Endosomal/Vacuolar pathway,4.2487532e-05,8.0,4.2487532e-05,-0.26490423,-0.011815992
Energy dependent regulation of mTOR by LKB1-AMPK,0.00041046616,25.0,0.00041046616,-0.2592795,-0.67858225
Entry of Influenza Virion into Host Cell via Endocytosis,0.0,1.0,0.0,-0.26555365,0.26398215
Enzymatic degradation of Dopamine by monoamine oxidase,4.7847214e-05,2.0,4.7847214e-05,-0.26482227,0.22506033
Enzymatic degradation of dopamine by COMT,7.758483e-05,2.0,7.758483e-05,-0.26436773,0.2254005
Ephrin signaling,7.42857e-06,13.0,7.42857e-06,-0.2654401,-0.2095629
Erythrocytes take up carbon dioxide and release oxygen,0.00078024785,8.0,0.00078024785,-0.2536272,-0.00337619
Erythrocytes take up oxygen and release carbon dioxide,6.257158e-05,4.0,6.257158e-05,-0.2645972,0.14629044
Essential fructosuria,0.0,1.0,0.0,-0.26555365,0.26398215
Essential pentosuria,0.0,1.0,0.0,-0.26555365,0.26398215
Establishment of Sister Chromatid Cohesion,0.00055405626,8.0,0.00055405626,-0.25708464,-0.005963757
Estrogen biosynthesis,0.11879687,3.0,0.11879687,1.5503143,1.5440522
Estrogen-dependent gene expression,0.020971663,68.0,0.020971663,0.05500841,-2.1405413
Ethanol oxidation,0.009744313,6.0,0.009744313,-0.11660711,0.17810896
Eukaryotic Translation Termination,0.060834486,35.0,0.060834486,0.664331,-0.38203725
Export of Viral Ribonucleoproteins from Nucleus,0.00090902206,3.0,0.00090902206,-0.2516588,0.19544283
Extrinsic Pathway of Fibrin Clot Formation,0.0027548412,4.0,0.0027548412,-0.22344458,0.17708936
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis,0.00061711716,37.0,0.00061711716,-0.25612074,-1.1498482
FCERI mediated Ca+2 mobilization,0.0010048695,19.0,0.0010048695,-0.25019374,-0.43496746
FCERI mediated MAPK activation,0.0024248115,21.0,0.0024248115,-0.22848924,-0.49766195
FCERI mediated NF-kB activation,0.0191721,55.0,0.0191721,0.027501216,-1.6480287
FCGR activation,0.00527032,7.0,0.00527032,-0.18499425,0.08745835
FGFR1 ligand binding and activation,0.058899965,11.0,0.058899965,0.634761,0.5430923
FGFR1 mutant receptor activation,0.0068349005,23.0,0.0068349005,-0.16107889,-0.5261499
FGFR2 alternative splicing,0.20572414,19.0,0.20572414,2.87904,1.9069734
FGFR2 ligand binding and activation,0.062329087,10.0,0.062329087,0.68717676,0.6217898
FGFR2 mutant receptor activation,0.00019219825,21.0,0.00019219825,-0.2626158,-0.52320254
FGFR3 ligand binding and activation,0.02902314,8.0,0.02902314,0.17807916,0.31971595
FGFR4 ligand binding and activation,0.036326896,11.0,0.036326896,0.28972062,0.28486168
FGFR4 mutant receptor activation,1.4921059e-05,2.0,1.4921059e-05,-0.26532558,0.22468366
FGFRL1 modulation of FGFR1 signaling,0.038289715,8.0,0.038289715,0.31972325,0.42572337
FMO oxidises nucleophiles,2.364278e-06,2.0,2.364278e-06,-0.26551753,0.22454
Fanconi Anemia Pathway,0.0027599444,25.0,0.0027599444,-0.22336656,-0.6517048
FasL/ CD95L signaling,0.0002489003,4.0,0.0002489003,-0.26174912,0.14842199
Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion,0.008348602,7.0,0.008348602,-0.13794123,0.12267317
Fatty acids,0.007956512,6.0,0.007956512,-0.1439345,0.15765692
Fibronectin matrix formation,1.4295855e-10,2.0,1.4295855e-10,-0.26555365,0.22451296
Folding of actin by CCT/TriC,0.0016587476,7.0,0.0016587476,-0.24019891,0.046142794
Formation of ATP by chemiosmotic coupling,0.0,1.0,0.0,-0.26555365,0.26398215
Formation of Incision Complex in GG-NER,0.009695918,36.0,0.009695918,-0.11734684,-1.0065198
Formation of RNA Pol II elongation complex ,0.13567846,46.0,0.13567846,1.8083575,0.03999946
Formation of Senescence-Associated Heterochromatin Foci (SAHF),0.000514852,6.0,0.000514852,-0.2576839,0.07252607
Formation of TC-NER Pre-Incision Complex,0.02479023,44.0,0.02479023,0.11337705,-1.1495976
Formation of a pool of free 40S subunits,0.28434938,43.0,0.28434938,4.080865,1.8591677
Formation of editosomes by ADAR proteins,0.0018476644,2.0,0.0018476644,-0.23731121,0.2456498
Formation of selenosugars for excretion,0.0,1.0,0.0,-0.26555365,0.26398215
Formation of the Early Elongation Complex,0.390366,27.0,0.390366,5.7013803,3.7034795
Formation of the Editosome,0.00051986024,7.0,0.00051986024,-0.25760734,0.0331142
"Formation of the active cofactor, UDP-glucuronate",1.0769314e-05,2.0,1.0769314e-05,-0.26538903,0.22463617
Formation of the cornified envelope,0.00013278595,54.0,0.00013278595,-0.26352397,-1.8263648
"Formation of the ternary complex, and subsequently, the 43S complex",0.060989615,26.0,0.060989615,0.6667023,-0.025040096
Formation of tubulin folding intermediates by CCT/TriC,0.041120183,14.0,0.041120183,0.36298832,0.22128828
Formation of xylulose-5-phosphate,0.0012113118,4.0,0.0012113118,-0.24703817,0.15943174
Free fatty acid receptors,2.1051273e-10,2.0,2.1051273e-10,-0.26555365,0.22451296
Fructose biosynthesis,0.0011133627,3.0,0.0011133627,-0.24853538,0.19778042
Fructose catabolism,0.00051538186,5.0,0.00051538186,-0.2576758,0.11200131
Fusion and Uncoating of the Influenza Virion,0.0,1.0,0.0,-0.26555365,0.26398215
G alpha (12/13) signalling events,0.01887837,63.0,0.01887837,0.023011412,-1.9671425
G alpha (z) signalling events,0.009406686,23.0,0.009406686,-0.12176789,-0.4967293
G beta:gamma signalling through PI3Kgamma,0.15714516,19.0,0.15714516,2.1364865,1.3512411
G beta:gamma signalling through PLC beta,0.52271456,17.0,0.52271456,7.724393,5.612208
G1/S-Specific Transcription,0.0015339772,10.0,0.0015339772,-0.24210607,-0.07369204
G2 Phase,0.003720256,4.0,0.003720256,-0.20868775,0.1881335
G2/M DNA replication checkpoint,0.00050792535,2.0,0.00050792535,-0.2577898,0.2303235
GAB1 signalosome,0.7807964,8.0,0.7807964,11.669299,8.9198265
GABA A (rho) receptor activation,3.7360223e-07,3.0,3.7360223e-07,-0.26554793,0.18504809
GABA A receptor activation,6.6744514e-07,9.0,6.6744514e-07,-0.26554346,-0.05176359
GABA B receptor activation,0.00018272859,24.0,0.00018272859,-0.26276055,-0.6417184
GABA synthesis,4.9699705e-10,2.0,4.9699705e-10,-0.26555365,0.22451296
GLI proteins bind promoters of Hh responsive genes to promote transcription,0.00061439985,8.0,0.00061439985,-0.2561623,-0.005273461
GLI3 is processed to GLI3R by the proteasome,0.013924184,39.0,0.013924184,-0.052715734,-1.0765569
GP1b-IX-V activation signalling,4.8970296e-06,6.0,4.8970296e-06,-0.26547882,0.06669229
GPVI-mediated activation cascade,0.014686789,24.0,0.014686789,-0.041058943,-0.47579533
GRB2 events in EGFR signaling,0.16767332,5.0,0.16767332,2.2974145,2.0242493
GRB2 events in ERBB2 signaling,0.098006904,10.0,0.098006904,1.2325295,1.0299358
GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0062654517,10.0,0.0062654517,-0.16978317,-0.019565076
GRB7 events in ERBB2 signaling,0.015021621,5.0,0.015021621,-0.035940874,0.2779493
GTP hydrolysis and joining of the 60S ribosomal subunit,0.104336254,51.0,0.104336254,1.3292767,-0.51589394
Galactose catabolism,0.00017540394,5.0,0.00017540394,-0.26287255,0.10811202
Gamma-carboxylation of protein precursors,0.00055604195,5.0,0.00055604195,-0.25705427,0.11246644
Gap junction assembly,0.00012881655,10.0,0.00012881655,-0.26358464,-0.08976675
Gap junction degradation,8.692218e-06,7.0,8.692218e-06,-0.2654208,0.027266562
Gap-filling DNA repair synthesis and ligation in GG-NER,0.00034829986,19.0,0.00034829986,-0.26022974,-0.44247845
Gap-filling DNA repair synthesis and ligation in TC-NER,0.01049689,50.0,0.01049689,-0.10510359,-1.5499252
Gastrin-CREB signalling pathway via PKC and MAPK,0.011755791,13.0,0.011755791,-0.085860685,-0.07516439
Generation of second messenger molecules,0.0012286785,13.0,0.0012286785,-0.2467727,-0.19559209
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,0.024516895,25.0,0.024516895,0.10919901,-0.40281034
Glucagon-type ligand receptors,0.018492699,22.0,0.018492699,0.01711623,-0.3533182
Glucocorticoid biosynthesis,0.01132559,5.0,0.01132559,-0.09243651,0.23566757
Gluconeogenesis,0.0073132617,23.0,0.0073132617,-0.1537669,-0.5206776
Glutamate Neurotransmitter Release Cycle,0.0005359892,12.0,0.0005359892,-0.25736082,-0.16404712
Glutathione synthesis and recycling,1.0437776e-05,7.0,1.0437776e-05,-0.26539412,0.02728652
Glycerophospholipid catabolism,0.16916023,4.0,0.16916023,2.3201427,2.0807283
Glycine degradation,8.3756786e-05,3.0,8.3756786e-05,-0.26427338,0.18600197
Glycogen breakdown (glycogenolysis),0.017616082,15.0,0.017616082,0.0037167184,-0.08706236
Glycogen storage disease type 0 (liver GYS2),8.2783336e-05,3.0,8.2783336e-05,-0.26428828,0.18599083
Glycogen storage disease type 0 (muscle GYS1),0.003238471,3.0,0.003238471,-0.21605206,0.22209115
Glycogen storage disease type II (GAA),0.00033786948,2.0,0.00033786948,-0.26038918,0.22837812
Glycogen storage disease type IV (GBE1),0.0011238963,3.0,0.0011238963,-0.24837437,0.19790092
Glycogen storage disease type Ia (G6PC),0.0,1.0,0.0,-0.26555365,0.26398215
Glycogen storage disease type Ib (SLC37A4),0.0,1.0,0.0,-0.26555365,0.26398215
Glycogen storage disease type XV (GYG1),0.0023228468,3.0,0.0023228468,-0.23004782,0.21161662
Glycogen synthesis,0.009933245,13.0,0.009933245,-0.11371917,-0.09601388
Glycoprotein hormones,1.0267884e-09,3.0,1.0267884e-09,-0.26555362,0.18504381
Glycosphingolipid metabolism,0.06446705,25.0,0.06446705,0.71985656,0.054210123
Golgi Associated Vesicle Biogenesis,0.00013100328,49.0,0.00013100328,-0.2635512,-1.6290394
Golgi Cisternae Pericentriolar Stack Reorganization,0.025090827,10.0,0.025090827,0.11797182,0.19579284
Growth hormone receptor signaling,0.00020689942,14.0,0.00020689942,-0.26239112,-0.24675018
HATs acetylate histones,0.0037909881,62.0,0.0037909881,-0.20760657,-2.1002693
HCN channels,0.002297921,4.0,0.002297921,-0.23042881,0.17186232
HDACs deacetylate histones,0.022385957,25.0,0.022385957,0.07662658,-0.42718777
HDL assembly,0.023586456,4.0,0.023586456,0.09497678,0.4153982
HDL clearance,2.0856925e-05,3.0,2.0856925e-05,-0.26523486,0.18528238
HDL remodeling,0.00028440717,5.0,0.00028440717,-0.26120636,0.109359
HDMs demethylate histones,0.00020530596,21.0,0.00020530596,-0.26241547,-0.5230526
HDR through Homologous Recombination (HRR),0.018673345,49.0,0.018673345,0.019877505,-1.4169194
HDR through MMEJ (alt-NHEJ),0.0025888444,9.0,0.0025888444,-0.22598192,-0.022155454
HDR through Single Strand Annealing (SSA),0.03665866,30.0,0.03665866,0.2947918,-0.46125728
HHAT G278V abrogates palmitoylation of Hh-Np,0.0,1.0,0.0,-0.26555365,0.26398215
HS-GAG biosynthesis,0.0043379297,18.0,0.0043379297,-0.1992463,-0.35736883
HS-GAG degradation,0.0033210847,11.0,0.0033210847,-0.21478926,-0.09271712
HSF1 activation,6.1879575e-05,12.0,6.1879575e-05,-0.26460782,-0.16947085
HSP90 chaperone cycle for steroid hormone receptors (SHR),2.2191047e-05,15.0,2.2191047e-05,-0.26521444,-0.28833234
Heme biosynthesis,0.008252781,7.0,0.008252781,-0.13940589,0.121577
Heme degradation,0.0030719612,3.0,0.0030719612,-0.21859725,0.22018634
Hereditary fructose intolerance,0.0,1.0,0.0,-0.26555365,0.26398215
Hh mutants that don't undergo autocatalytic processing are degraded by ERAD,0.010743941,37.0,0.010743941,-0.10132729,-1.0339998
Histidine catabolism,0.024891231,5.0,0.024891231,0.114920914,0.39085534
Hormone ligand-binding receptors,0.0057440014,6.0,0.0057440014,-0.17775382,0.13234632
HuR (ELAVL1) binds and stabilizes mRNA,0.00805203,8.0,0.00805203,-0.14247447,0.0798113
Hyaluronan biosynthesis and export,0.001428415,3.0,0.001428415,-0.24371965,0.20138454
Hyaluronan uptake and degradation,0.005603552,10.0,0.005603552,-0.17990065,-0.027137058
Hydrolysis of LPC,0.00014886048,7.0,0.00014886048,-0.26327825,0.028870042
Hydrolysis of LPE,0.00026270753,2.0,0.00026270753,-0.26153806,0.22751828
Hydroxycarboxylic acid-binding receptors,0.0,1.0,0.0,-0.26555365,0.26398215
Hypusine synthesis from eIF5A-lysine,0.0033537487,5.0,0.0033537487,-0.21428998,0.14447156
IKBKB deficiency causes SCID,0.00064295117,2.0,0.00064295117,-0.25572583,0.23186816
IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR),0.00038937808,3.0,0.00038937808,-0.25960183,0.18949822
IL-6-type cytokine receptor ligand interactions,0.00031639833,11.0,0.00031639833,-0.26071736,-0.12709004
IP3 and IP4 transport between cytosol and nucleus,0.0,1.0,0.0,-0.26555365,0.26398215
IP6 and IP7 transport between cytosol and nucleus,0.0,1.0,0.0,-0.26555365,0.26398215
IPs transport between ER lumen and cytosol,0.0,1.0,0.0,-0.26555365,0.26398215
IPs transport between ER lumen and nucleus,0.0,1.0,0.0,-0.26555365,0.26398215
IPs transport between cytosol and ER lumen,0.0,1.0,0.0,-0.26555365,0.26398215
IPs transport between nucleus and ER lumen,0.0,1.0,0.0,-0.26555365,0.26398215
IPs transport between nucleus and cytosol,0.0,1.0,0.0,-0.26555365,0.26398215
IRAK4 deficiency (TLR2/4),1.1416195e-05,5.0,1.1416195e-05,-0.26537916,0.10623605
IRAK4 deficiency (TLR5),0.00046255943,4.0,0.00046255943,-0.2584832,0.1508662
IRF3 mediated activation of type 1 IFN,0.0018585816,3.0,0.0018585816,-0.23714434,0.20630553
IRF3-mediated induction of type I IFN,8.827116e-06,3.0,8.827116e-06,-0.26541874,0.18514477
IRS activation,0.027096258,4.0,0.027096258,0.14862582,0.45554948
IRS-mediated signalling,0.033939492,34.0,0.033939492,0.25322798,-0.6502406
ISG15 antiviral mechanism,0.0009316978,56.0,0.0009316978,-0.25131223,-1.896164
IkBA variant leads to EDA-ID,0.0005655522,7.0,0.0005655522,-0.2569089,0.033636905
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0060759694,31.0,0.0060759694,-0.17267951,-0.8505853
Import of palmitoyl-CoA into the mitochondrial matrix,0.0011782753,9.0,0.0011782753,-0.24754314,-0.038292024
Inactivation of APC/C via direct inhibition of the APC/C complex,0.06385949,15.0,0.06385949,0.71056974,0.4419515
Inactivation of CDC42 and RAC1,0.000248329,7.0,0.000248329,-0.26175782,0.030007945
Influenza Viral RNA Transcription and Replication,0.07060668,56.0,0.07060668,0.8137038,-1.0990984
Influenza Virus Induced Apoptosis,0.0,1.0,0.0,-0.26555365,0.26398215
Inhibition of Signaling by Overexpressed EGFR,0.00090374507,2.0,0.00090374507,-0.2517395,0.2348516
Inhibition of TSC complex formation by PKB,0.0016664529,4.0,0.0016664529,-0.24008112,0.16463846
InlA-mediated entry of Listeria monocytogenes into host cells,0.088335454,8.0,0.088335454,1.0846968,0.99823505
InlB-mediated entry of Listeria monocytogenes into host cell,0.014855936,12.0,0.014855936,-0.038473453,-0.0002302763
Inositol transporters,0.0040582097,4.0,0.0040582097,-0.20352195,0.19199963
Insulin effects increased synthesis of Xylulose-5-Phosphate,0.01100313,2.0,0.01100313,-0.09736547,0.3503862
Insulin processing,0.10788508,20.0,0.10788508,1.3835223,0.74824804
Insulin receptor recycling,0.22563271,17.0,0.22563271,3.1833522,2.2136612
Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA,0.0019120739,7.0,0.0019120739,-0.23632668,0.049040794
Integrin cell surface interactions,0.16647704,27.0,0.16647704,2.279129,1.1422424
Interaction With Cumulus Cells,0.0,1.0,0.0,-0.26555365,0.26398215
Interaction With The Zona Pellucida,0.00037164323,6.0,0.00037164323,-0.2598729,0.07088778
Interaction between L1 and Ankyrins,0.0015707155,9.0,0.0015707155,-0.24154453,-0.03380261
Interaction between PHLDA1 and AURKA,0.0,1.0,0.0,-0.26555365,0.26398215
Interactions of Rev with host cellular proteins,0.0066273296,29.0,0.0066273296,-0.1642517,-0.7653395
Interactions of Tat with host cellular proteins,0.0002059944,2.0,0.0002059944,-0.26240495,0.2268695
Interactions of Vpr with host cellular proteins,0.0015929415,28.0,0.0015929415,-0.24120477,-0.7834625
Interconversion of 2-oxoglutarate and 2-hydroxyglutarate,0.018440505,4.0,0.018440505,0.016318433,0.3565297
Interconversion of nucleotide di- and triphosphates,0.013231193,15.0,0.013231193,-0.06330845,-0.13722448
Interconversion of polyamines,0.0,1.0,0.0,-0.26555365,0.26398215
Interleukin receptor SHC signaling,0.0003579339,17.0,0.0003579339,-0.26008248,-0.36342987
Interleukin-1 processing,3.148234e-05,3.0,3.148234e-05,-0.26507244,0.18540396
Interleukin-10 signaling,9.693552e-06,7.0,9.693552e-06,-0.2654055,0.027277993
Interleukin-12 signaling,2.0367454e-06,23.0,2.0367454e-06,-0.26552254,-0.6043163
Interleukin-15 signaling,1.9371178e-05,10.0,1.9371178e-05,-0.26525757,-0.09101877
Interleukin-18 signaling,8.245325e-06,2.0,8.245325e-06,-0.26542762,0.2246073
Interleukin-2 signaling,4.6158173e-05,10.0,4.6158173e-05,-0.2648481,-0.090712346
Interleukin-20 family signaling,4.6853984e-05,16.0,4.6853984e-05,-0.26483747,-0.3275194
Interleukin-21 signaling,8.508077e-05,8.0,8.508077e-05,-0.26425317,-0.011328738
Interleukin-23 signaling,1.9140187e-05,4.0,1.9140187e-05,-0.26526108,0.14579359
Interleukin-27 signaling,1.8381632e-05,9.0,1.8381632e-05,-0.26527268,-0.05156093
Interleukin-33 signaling,3.827662e-05,3.0,3.827662e-05,-0.26496857,0.1854817
Interleukin-35 Signalling,2.4555533e-05,8.0,2.4555533e-05,-0.26517832,-0.012021133
Interleukin-36 pathway,4.4827862e-05,4.0,4.4827862e-05,-0.26486844,0.14608747
Interleukin-37 signaling,8.798081e-05,15.0,8.798081e-05,-0.26420885,-0.28757975
Interleukin-38 signaling,3.501134e-05,2.0,3.501134e-05,-0.2650185,0.22491348
Interleukin-4 and Interleukin-13 signaling,0.00035320577,54.0,0.00035320577,-0.26015472,-1.8238434
Interleukin-6 signaling,4.6562847e-05,8.0,4.6562847e-05,-0.26484194,-0.011769379
Interleukin-7 signaling,0.00022847852,18.0,0.00022847852,-0.26206127,-0.40438002
Interleukin-9 signaling,0.00018865477,8.0,0.00018865477,-0.26266998,-0.010143887
Intestinal hexose absorption,1.1085648e-08,2.0,1.1085648e-08,-0.2655535,0.2245131
Intestinal infectious diseases,0.00016525044,2.0,0.00016525044,-0.26302773,0.22640337
Intestinal lipid absorption,8.981036e-06,2.0,8.981036e-06,-0.26541638,0.22461572
Intestinal saccharidase deficiencies,0.0,1.0,0.0,-0.26555365,0.26398215
Intra-Golgi traffic,7.8540295e-05,33.0,7.8540295e-05,-0.26435313,-0.99813277
Intracellular oxygen transport,2.813439e-09,2.0,2.813439e-09,-0.2655536,0.22451301
Intraflagellar transport,0.00011101388,28.0,0.00011101388,-0.26385677,-0.8004155
Intrinsic Pathway of Fibrin Clot Formation,0.0073226793,7.0,0.0073226793,-0.15362296,0.11093686
Invadopodia formation,0.0006216917,4.0,0.0006216917,-0.2560508,0.15268663
Ion homeostasis,0.031071281,20.0,0.031071281,0.20938598,-0.13048387
Ion influx/efflux at host-pathogen interface,0.0017299022,3.0,0.0017299022,-0.23911127,0.20483348
Ion transport by P-type ATPases,0.059382405,28.0,0.059382405,0.64213526,-0.12236455
Ionotropic activity of kainate receptors,0.00058066944,6.0,0.00058066944,-0.25667784,0.07327902
Josephin domain DUBs,0.00044597965,7.0,0.00044597965,-0.25873664,0.032269016
KSRP (KHSRP) binds and destabilizes mRNA,0.014616226,13.0,0.014616226,-0.04213754,-0.042441674
Keratan sulfate biosynthesis,0.049339607,15.0,0.049339607,0.48862624,0.2758474
Keratan sulfate degradation,0.011684035,6.0,0.011684035,-0.08695751,0.20029892
Kinesins,0.011915116,19.0,0.011915116,-0.08342533,-0.31015676
L13a-mediated translational silencing of Ceruloplasmin expression,0.0069463393,51.0,0.0069463393,-0.15937549,-1.6300118
LDL clearance,3.68231e-05,12.0,3.68231e-05,-0.2649908,-0.16975749
LDL remodeling,0.0,1.0,0.0,-0.26555365,0.26398215
LGI-ADAM interactions,0.00010749082,8.0,0.00010749082,-0.2639106,-0.011072364
LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production,0.0011817472,5.0,0.0011817472,-0.24749008,0.11962437
Lactose synthesis,0.00031756843,4.0,0.00031756843,-0.26069948,0.14920753
Laminin interactions,0.0050498797,13.0,0.0050498797,-0.18836379,-0.15187845
Late Phase of HIV Life Cycle,0.00053939363,102.0,0.00053939363,-0.25730875,-3.7162333
Ligand-receptor interactions,2.4819024e-05,4.0,2.4819024e-05,-0.26517427,0.14585857
Linoleic acid (LA) metabolism,0.0005053661,4.0,0.0005053661,-0.2578289,0.15135589
Lipid particle organization,0.0056635155,5.0,0.0056635155,-0.17898406,0.17089476
Localization of the PINCH-ILK-PARVIN complex to focal adhesions,0.0,1.0,0.0,-0.26555365,0.26398215
Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling,0.00097069336,6.0,0.00097069336,-0.25071615,0.07774078
Lysine catabolism,0.019761361,9.0,0.019761361,0.036508355,0.17429414
Lysosomal oligosaccharide catabolism,0.00014133472,5.0,0.00014133472,-0.2633933,0.10772228
Lysosome Vesicle Biogenesis,5.7028315e-06,28.0,5.7028315e-06,-0.26546648,-0.80162024
Lysosphingolipid and LPA receptors,0.003936888,6.0,0.003936888,-0.2053764,0.11167337
MAP kinase activation,0.0043558613,46.0,0.0043558613,-0.19897221,-1.4623005
MAP2K and MAPK activation,0.024538524,29.0,0.024538524,0.109529614,-0.5604396
MAPK1 (ERK2) activation,0.015974348,3.0,0.015974348,-0.021377977,0.36778662
MAPK3 (ERK1) activation,0.0010837638,3.0,0.0010837638,-0.24898781,0.19744182
MAPK6/MAPK4 signaling,0.19061066,61.0,0.19061066,2.6480231,0.076373585
MASTL Facilitates Mitotic Progression,0.0003749228,8.0,0.0003749228,-0.2598228,-0.008013013
MET Receptor Activation,0.016935555,3.0,0.016935555,-0.0066854637,0.3787826
MET activates PI3K/AKT signaling,0.048103034,5.0,0.048103034,0.46972463,0.65639293
MET activates PTK2 signaling,0.0070880963,4.0,0.0070880963,-0.15720865,0.2266608
MET activates PTPN11,0.0037579383,4.0,0.0037579383,-0.20811173,0.18856458
MET activates RAP1 and RAC1,0.07505662,10.0,0.07505662,0.8817233,0.7673898
MET activates RAS signaling,0.16032316,8.0,0.16032316,2.1850638,1.8217576
MET activates STAT3,0.05733641,3.0,0.05733641,0.61086124,0.84095895
MET interacts with TNS proteins,6.5126536e-05,2.0,6.5126536e-05,-0.26455817,0.225258
MET receptor recycling,0.023157712,6.0,0.023157712,0.08842323,0.33155513
MGMT-mediated DNA damage reversal,0.002740381,2.0,0.002740381,-0.2236656,0.2558623
MHC class II antigen presentation,0.011807642,66.0,0.011807642,-0.085068114,-2.1664371
MPS I - Hurler syndrome,0.0,1.0,0.0,-0.26555365,0.26398215
MPS II - Hunter syndrome,0.0,1.0,0.0,-0.26555365,0.26398215
MPS IIIA - Sanfilippo syndrome A,0.0,1.0,0.0,-0.26555365,0.26398215
MPS IIIB - Sanfilippo syndrome B,0.0,1.0,0.0,-0.26555365,0.26398215
MPS IIIC - Sanfilippo syndrome C,0.0,1.0,0.0,-0.26555365,0.26398215
MPS IIID - Sanfilippo syndrome D,0.0,1.0,0.0,-0.26555365,0.26398215
MPS IV - Morquio syndrome A,0.0,1.0,0.0,-0.26555365,0.26398215
MPS IV - Morquio syndrome B,0.0,1.0,0.0,-0.26555365,0.26398215
MPS IX - Natowicz syndrome,0.0,1.0,0.0,-0.26555365,0.26398215
MPS VI - Maroteaux-Lamy syndrome,0.0,1.0,0.0,-0.26555365,0.26398215
MPS VII - Sly syndrome,0.0,1.0,0.0,-0.26555365,0.26398215
MTF1 activates gene expression,0.0042405976,4.0,0.0042405976,-0.20073406,0.19408607
Macroautophagy,0.0031435855,44.0,0.0031435855,-0.21750243,-1.3972303
Major pathway of rRNA processing in the nucleolus and cytosol,0.026764309,96.0,0.026764309,0.14355181,-3.1794114
Meiotic recombination,0.016440958,16.0,0.016440958,-0.0142456265,-0.13997467
Meiotic synapsis,8.361845e-05,23.0,8.361845e-05,-0.26427552,-0.60338306
Melanin biosynthesis,4.523275e-05,3.0,4.523275e-05,-0.26486227,0.18556125
Metabolism of Angiotensinogen to Angiotensins,0.0056610885,5.0,0.0056610885,-0.17902116,0.170867
Metabolism of folate and pterines,0.0012041973,11.0,0.0012041973,-0.24714693,-0.11693383
Metabolism of ingested H2SeO4 and H2SeO3 into H2Se,2.0898438e-05,4.0,2.0898438e-05,-0.2652342,0.1458137
Metabolism of ingested MeSeO2H into MeSeH,0.0073941834,2.0,0.0073941834,-0.15252997,0.3091007
"Metabolism of ingested SeMet, Sec, MeSec into H2Se",0.05376401,7.0,0.05376401,0.5562554,0.6422149
Metabolism of serotonin,0.0,2.0,0.0,-0.26555365,0.22451296
Metabolism of vitamin K,0.0015271907,3.0,0.0015271907,-0.24220982,0.20251451
Metal sequestration by antimicrobial proteins,1.27391295e-05,2.0,1.27391295e-05,-0.26535895,0.2246587
Metalloprotease DUBs,0.00013713747,16.0,0.00013713747,-0.26345745,-0.3264866
Metallothioneins bind metals,4.6066566e-06,3.0,4.6066566e-06,-0.26548326,0.1850965
Methionine salvage pathway,0.004258462,6.0,0.004258462,-0.200461,0.115352094
Methylation,3.611341e-05,10.0,3.611341e-05,-0.26500165,-0.09082725
Methylation of MeSeH for excretion,0.008269225,2.0,0.008269225,-0.13915454,0.31911096
MicroRNA (miRNA) biogenesis,0.004241781,16.0,0.004241781,-0.20071597,-0.27953038
Mineralocorticoid biosynthesis,4.130637e-05,3.0,4.130637e-05,-0.2649223,0.18551634
Miscellaneous substrates,0.006287171,6.0,0.006287171,-0.1694512,0.13856006
Miscellaneous transport and binding events,0.00029832986,17.0,0.00029832986,-0.26099354,-0.36411172
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta),0.00030199497,10.0,0.00030199497,-0.26093754,-0.08778565
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha),0.00012828004,11.0,0.00012828004,-0.26359284,-0.12924206
Misspliced GSK3beta mutants stabilize beta-catenin,0.00011507121,12.0,0.00011507121,-0.26379475,-0.16886234
Misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling,8.7522436e-05,4.0,8.7522436e-05,-0.26421586,0.14657585
Mitochondrial ABC transporters,1.3205022e-05,5.0,1.3205022e-05,-0.26535183,0.1062565
Mitochondrial protein import,0.0006827048,38.0,0.0006827048,-0.2551182,-1.1885672
Mitochondrial tRNA aminoacylation,0.10862321,14.0,0.10862321,1.3948048,0.9935072
Mitochondrial transcription initiation,0.0060271914,3.0,0.0060271914,-0.17342511,0.2539935
Mitochondrial transcription termination,0.0056668464,2.0,0.0056668464,-0.17893316,0.28934035
Mitochondrial translation elongation,0.0032606118,51.0,0.0032606118,-0.21571364,-1.6721756
Mitochondrial translation initiation,0.0027710781,51.0,0.0027710781,-0.22319639,-1.6777759
Mitochondrial translation termination,0.0011094074,51.0,0.0011094074,-0.24859582,-1.696785
Mitotic Anaphase,0.0016200314,110.0,1.4727559e-05,-0.26532853,-4.0196247
Mitotic Metaphase/Anaphase Transition,6.899861e-05,2.0,6.899861e-05,-0.264499,0.22530228
Molecules associated with elastic fibres,0.0068727587,15.0,0.0068727587,-0.16050021,-0.20996347
Molybdenum cofactor biosynthesis,0.019318733,6.0,0.019318733,0.029742572,0.2876381
Mtb iron assimilation by chelation,0.0,1.0,0.0,-0.26555365,0.26398215
Multifunctional anion exchangers,0.00013475183,5.0,0.00013475183,-0.26349393,0.10764698
MyD88 deficiency (TLR2/4),0.00012149823,4.0,0.00012149823,-0.2636965,0.14696455
MyD88 deficiency (TLR5),1.1453546e-05,2.0,1.1453546e-05,-0.2653786,0.22464398
MyD88 dependent cascade initiated on endosome,0.013531968,56.0,0.013531968,-0.05871095,-1.7520198
MyD88-independent TLR4 cascade ,0.11329079,64.0,0.11329079,1.4661511,-0.9265552
Myoclonic epilepsy of Lafora,0.0013021551,9.0,0.0013021551,-0.24564959,-0.036874875
N-glycan antennae elongation in the medial/trans-Golgi,0.023725662,17.0,0.023725662,0.097104624,-0.09610851
N-glycan trimming and elongation in the cis-Golgi,0.008277074,4.0,0.008277074,-0.13903455,0.24026245
NADE modulates death signalling,0.0007086679,5.0,0.0007086679,-0.25472134,0.11421244
NADPH regeneration,0.11419094,2.0,0.11419094,1.4799105,1.5308309
NCAM1 interactions,0.00065907795,23.0,0.00065907795,-0.25547934,-0.5967999
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10,0.005594444,10.0,0.005594444,-0.18003987,-0.027241258
NF-kB is activated and signals survival,0.00032752828,11.0,0.00032752828,-0.26054725,-0.12696272
NFG and proNGF binds to p75NTR,0.001222971,2.0,0.001222971,-0.24685994,0.23850346
NGF processing,0.032665852,3.0,0.032665852,0.23375978,0.5587335
NIK-->noncanonical NF-kB signaling,0.008328274,38.0,0.008328274,-0.13825195,-1.1011037
NOD1/2 Signaling Pathway,0.014075568,25.0,0.014075568,-0.050401762,-0.5222567
NOSIP mediated eNOS trafficking,0.0,1.0,0.0,-0.26555365,0.26398215
NOSTRIN mediated eNOS trafficking,0.0030368394,4.0,0.0030368394,-0.21913409,0.18031536
NOTCH1 Intracellular Domain Regulates Transcription,0.03008743,32.0,0.03008743,0.19434734,-0.6153689
NOTCH2 Activation and Transmission of Signal to the Nucleus,0.025085498,16.0,0.025085498,0.117890365,-0.041083146
NOTCH2 intracellular domain regulates transcription,0.006174991,8.0,0.006174991,-0.17116593,0.058338415
NOTCH3 Intracellular Domain Regulates Transcription,0.057068337,17.0,0.057068337,0.6067636,0.28532395
NOTCH4 Activation and Transmission of Signal to the Nucleus,9.380287e-05,8.0,9.380287e-05,-0.26411983,-0.011228948
NOTCH4 Intracellular Domain Regulates Transcription,0.0018952354,10.0,0.0018952354,-0.23658405,-0.06955933
NR1D1 (REV-ERBA) represses gene expression,9.6670306e-08,3.0,9.6670306e-08,-0.2655522,0.18504491
NRAGE signals death through JNK,0.023469113,43.0,0.023469113,0.09318314,-1.1252419
NRIF signals cell death from the nucleus,0.00027872343,13.0,0.00027872343,-0.26129326,-0.20645937
NS1 Mediated Effects on Host Pathways,0.0037395286,30.0,0.0037395286,-0.20839316,-0.8378445
NTF3 activates NTRK2 (TRKB) signaling,0.067020975,3.0,0.067020975,0.75889456,0.9517481
NTF3 activates NTRK3 signaling,0.0036466783,3.0,0.0036466783,-0.20981242,0.22676094
NTF4 activates NTRK2 (TRKB) signaling,0.41174504,2.0,0.41174504,6.0281696,4.93478
NTRK3 as a dependence receptor,0.062419463,4.0,0.062419463,0.68855816,0.85963875
Na+/Cl- dependent neurotransmitter transporters,0.00010079973,6.0,0.00010079973,-0.2640129,0.067789406
Nectin/Necl  trans heterodimerization,0.0024381017,2.0,0.0024381017,-0.22828609,0.25240427
Neddylation,0.0102381725,162.0,6.31986e-05,-0.26458764,-5.9734316
Negative regulation of FGFR1 signaling,0.17584838,26.0,0.17584838,2.4223745,1.2889173
Negative regulation of FGFR2 signaling,0.28326255,25.0,0.28326255,4.064252,2.5571795
Negative regulation of FGFR3 signaling,0.67450315,23.0,0.67450315,10.044556,7.111819
Negative regulation of FGFR4 signaling,0.20724337,26.0,0.20724337,2.9022622,1.6480688
Negative regulation of MAPK pathway,0.0032329774,28.0,0.0032329774,-0.21613602,-0.76470095
Negative regulation of MET activity,0.072818205,17.0,0.072818205,0.847508,0.46549872
Negative regulation of NOTCH4 signaling,0.00073715893,36.0,0.00073715893,-0.25428584,-1.1090058
Negative regulation of TCF-dependent signaling by DVL-interacting proteins,0.00024246404,5.0,0.00024246404,-0.26184747,0.10887918
Negative regulation of TCF-dependent signaling by WNT ligand antagonists,0.0018602186,9.0,0.0018602186,-0.23711932,-0.030490758
Negative regulation of activity of TFAP2 (AP-2) family transcription factors,0.00036027282,9.0,0.00036027282,-0.26004672,-0.047649786
Negative regulators of DDX58/IFIH1 signaling,0.0045172004,28.0,0.0045172004,-0.19650605,-0.7500097
Nephrin family interactions,0.00025117755,15.0,0.00025117755,-0.26171428,-0.28571284
Netrin mediated repulsion signals,5.7924157e-05,6.0,5.7924157e-05,-0.26466826,0.06729892
Neurexins and neuroligins,0.007571603,34.0,0.007571603,-0.14981802,-0.9518831
Neurofascin interactions,4.7720077e-06,5.0,4.7720077e-06,-0.26548073,0.10616004
Neurophilin interactions with VEGF and VEGFR,2.2762596e-09,2.0,2.2762596e-09,-0.26555362,0.22451298
Neutrophil degranulation,0.08055175,255.0,0.00031588922,-0.26072514,-8.839693
Nicotinamide salvaging,0.0039950563,11.0,0.0039950563,-0.20448728,-0.08500704
NoRC negatively regulates rRNA expression,0.002133486,35.0,0.002133486,-0.2329423,-1.053563
Noncanonical activation of NOTCH3,0.0015358845,6.0,0.0015358845,-0.24207692,0.08420645
Nonhomologous End-Joining (NHEJ),0.013108515,27.0,0.013108515,-0.06518363,-0.6122579
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC),0.01463791,54.0,0.01463791,-0.04180609,-1.6604296
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC),0.0014661716,38.0,0.0014661716,-0.24314252,-1.1796045
Norepinephrine Neurotransmitter Release Cycle,4.02257e-05,8.0,4.02257e-05,-0.2649388,-0.011841866
Notch-HLH transcription pathway,0.0009940558,12.0,0.0009940558,-0.25035903,-0.15880696
NrCAM interactions,0.0021590693,5.0,0.0021590693,-0.23255123,0.1308047
Nuclear Envelope Breakdown,0.04573234,35.0,0.04573234,0.43348742,-0.55480224
Nuclear Events (kinase and transcription factor activation),0.15895724,19.0,0.15895724,2.164185,1.371971
Nuclear Receptor transcription pathway,0.0010346177,33.0,0.0010346177,-0.24973904,-0.9871955
Nuclear signaling by ERBB4,0.005183047,18.0,0.005183047,-0.18632828,-0.3477009
Nucleotide-like (purinergic) receptors,0.022180356,5.0,0.022180356,0.07348387,0.35984358
O-glycosylation of TSR domain-containing proteins,0.0011238178,12.0,0.0011238178,-0.24837556,-0.15732251
Olfactory Signaling Pathway,0.085747354,219.0,0.00039154044,-0.25956878,-7.3593674
Oncogene Induced Senescence,0.012468536,24.0,0.012468536,-0.07496602,-0.50117165
Opioid Signalling,0.13531923,51.0,0.13531923,1.8028666,-0.16145584
Opsins,0.012034512,8.0,0.012034512,-0.08160029,0.12536997
Orc1 removal from chromatin,0.0009890399,49.0,0.0009890399,-0.2504357,-1.6192237
Organic anion transport,5.7510255e-07,3.0,5.7510255e-07,-0.26554486,0.18505038
Organic anion transporters,0.0049541504,4.0,0.0049541504,-0.18982707,0.20224895
Organic cation transport,0.000121033525,2.0,0.000121033525,-0.2637036,0.22589755
Other interleukin signaling,5.513775e-05,18.0,5.513775e-05,-0.26471084,-0.40636298
Other semaphorin interactions,0.00090177014,10.0,0.00090177014,-0.25176966,-0.08092435
Ovarian tumor domain proteases,0.0007961579,28.0,0.0007961579,-0.253384,-0.79257756
Oxidative Stress Induced Senescence,0.02212759,42.0,0.02212759,0.0726773,-1.1011193
Oxygen-dependent asparagine hydroxylation of Hypoxia-inducible Factor Alpha,9.300496e-06,3.0,9.300496e-06,-0.2654115,0.18515019
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.001600132,40.0,0.001600132,-0.24109487,-1.2570103
PAOs oxidise polyamines to amines,0.0,1.0,0.0,-0.26555365,0.26398215
PCNA-Dependent Long Patch Base Excision Repair,0.0029536206,15.0,0.0029536206,-0.22040613,-0.2547975
PD-1 signaling,0.0008405198,8.0,0.0008405198,-0.2527059,-0.0026866754
PECAM1 interactions,0.00015410768,10.0,0.00015410768,-0.26319805,-0.08947742
PI and PC transport between ER and Golgi membranes,0.012519255,3.0,0.012519255,-0.07419076,0.32826117
PI3K events in ERBB2 signaling,0.0055946815,11.0,0.0055946815,-0.18003623,-0.06670769
PI3K events in ERBB4 signaling,0.00010436742,7.0,0.00010436742,-0.26395833,0.028361045
PI3K/AKT activation,0.049414683,8.0,0.049414683,0.4897738,0.5529904
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",0.118397236,62.0,0.118397236,1.5442057,-0.7892005
PIPs transport between Golgi and plasma membranes,0.0,1.0,0.0,-0.26555365,0.26398215
PIPs transport between early and late endosome membranes,0.0,1.0,0.0,-0.26555365,0.26398215
PIPs transport between early endosome and Golgi membranes,0.0,1.0,0.0,-0.26555365,0.26398215
PIPs transport between late endosome and Golgi membranes,0.0,1.0,0.0,-0.26555365,0.26398215
PIPs transport between plasma and early endosome membranes,0.0,1.0,0.0,-0.26555365,0.26398215
PIWI-interacting RNA (piRNA) biogenesis,0.0057914085,17.0,0.0057914085,-0.17702916,-0.30127218
PKA activation in glucagon signalling,0.037038513,9.0,0.037038513,0.30059803,0.37194076
PKA-mediated phosphorylation of key metabolic factors,0.5325917,2.0,0.5325917,7.87537,6.317238
PKMTs methylate histone lysines,0.0029533652,35.0,0.0029533652,-0.22041003,-1.0441837
PLC-gamma1 signalling,0.003429847,3.0,0.003429847,-0.21312678,0.22428048
PLCG1 events in ERBB2 signaling,0.037117448,4.0,0.037117448,0.30180457,0.57018954
POLB-Dependent Long Patch Base Excision Repair,0.0047631413,6.0,0.0047631413,-0.19274673,0.121125504
"POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation",0.006619512,9.0,0.006619512,-0.16437119,0.023954455
"POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation",0.0010757517,7.0,0.0010757517,-0.24911027,0.03947347
PP2A-mediated dephosphorylation of key metabolic factors,0.0067624594,5.0,0.0067624594,-0.16218618,0.18346642
PPARA activates gene expression,0.00025855136,28.0,0.00025855136,-0.26160157,-0.7987277
PRC2 methylates histones and DNA,0.00040424187,13.0,0.00040424187,-0.25937462,-0.20502347
PTEN Loss of Function in Cancer,0.0,1.0,0.0,-0.26555365,0.26398215
PTK6 Activates STAT3,0.0012027826,3.0,0.0012027826,-0.24716854,0.19880337
PTK6 Down-Regulation,0.000102045124,3.0,0.000102045124,-0.26399386,0.18621117
PTK6 Expression,0.00082902896,5.0,0.00082902896,-0.25288153,0.11558937
PTK6 Regulates Cell Cycle,0.00083810184,7.0,0.00083810184,-0.2527429,0.03675479
PTK6 Regulates Proteins Involved in RNA Processing,0.0043476312,5.0,0.0043476312,-0.19909799,0.15584135
"PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases",0.00036106945,12.0,0.00036106945,-0.26003453,-0.16604817
PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1,0.0043219584,9.0,0.0043219584,-0.19949041,-0.0023290145
PTK6 promotes HIF1A stabilization,0.0007903617,4.0,0.0007903617,-0.2534726,0.15461618
Packaging Of Telomere Ends,0.003048483,7.0,0.003048483,-0.21895611,0.062041048
Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0019741924,28.0,0.0019741924,-0.23537716,-0.77910113
Passive transport by Aquaporins,0.01197018,6.0,0.01197018,-0.082583636,0.20357236
Peptide chain elongation,0.0023928268,34.0,0.0023928268,-0.22897814,-1.0111271
Peptide ligand-binding receptors,0.038971737,66.0,0.038971737,0.33014828,-1.8556863
Phase 0 - rapid depolarisation,0.011423867,18.0,0.011423867,-0.0909343,-0.27630734
Phase 1 - inactivation of fast Na+ channels,0.002502088,7.0,0.002502088,-0.22730803,0.05579041
Phase 2 - plateau phase,0.033087146,21.0,0.033087146,0.24019945,-0.146892
Phase 3 - rapid repolarisation,0.00041937034,8.0,0.00041937034,-0.25914338,-0.007504528
Phase 4 - resting membrane potential,0.007027939,9.0,0.007027939,-0.1581282,0.028626762
Phenylalanine and tyrosine catabolism,0.002247593,5.0,0.002247593,-0.23119812,0.13181739
Phenylketonuria,0.0,1.0,0.0,-0.26555365,0.26398215
Phosphate bond hydrolysis by NTPDase proteins,0.0029458522,7.0,0.0029458522,-0.22052488,0.060866978
Phosphate bond hydrolysis by NUDT proteins,0.0057348884,6.0,0.0057348884,-0.1778931,0.13224207
Phosphorylation of CD3 and TCR zeta chains,0.0023663815,6.0,0.0023663815,-0.22938237,0.09370714
Physiological factors,6.6513494e-05,5.0,6.6513494e-05,-0.26453698,0.10686636
Pink/Parkin Mediated Mitophagy,0.0024815958,16.0,0.0024815958,-0.22762127,-0.2996665
Plasmalogen biosynthesis,0.03973165,3.0,0.03973165,0.34176394,0.63956463
Platelet Adhesion to exposed collagen,3.076955e-05,8.0,3.076955e-05,-0.26508334,-0.011950051
Platelet degranulation ,0.20008372,69.0,0.20008372,2.7928233,-0.13101038
Platelet sensitization by LDL,0.002572293,11.0,0.002572293,-0.22623491,-0.10128313
Polo-like kinase mediated events,0.0009734415,8.0,0.0009734415,-0.25067416,-0.0011661085
Polymerase switching,0.012559418,11.0,0.012559418,-0.07357685,0.012967259
Post NMDA receptor activation events,0.0005445661,22.0,0.0005445661,-0.2572297,-0.5586407
Post-chaperonin tubulin folding pathway,0.002817262,10.0,0.002817262,-0.22249044,-0.059011567
Post-transcriptional silencing by small RNAs,0.004190998,7.0,0.004190998,-0.20149222,0.07511115
Post-translational protein phosphorylation,0.0017032118,61.0,0.0017032118,-0.23951924,-2.084684
Potassium transport channels,0.013149096,3.0,0.013149096,-0.06456334,0.3354664
Pre-NOTCH Processing in Golgi,0.0009089007,7.0,0.0009089007,-0.25166067,0.037564725
Pre-NOTCH Processing in the Endoplasmic Reticulum,0.00054211786,6.0,0.00054211786,-0.25726715,0.072837986
Pre-NOTCH Transcription and Translation,0.007891244,29.0,0.007891244,-0.14493215,-0.75088066
Prefoldin mediated transfer of substrate  to CCT/TriC,0.0044629583,15.0,0.0044629583,-0.19733517,-0.23753102
Pregnenolone biosynthesis,0.0022521387,8.0,0.0022521387,-0.23112862,0.013461903
Presynaptic depolarization and calcium channel opening,0.00056011096,9.0,0.00056011096,-0.2569921,-0.04536369
Presynaptic function of Kainate receptors,3.108805e-05,17.0,3.108805e-05,-0.26507849,-0.36716893
Processing of DNA double-strand break ends,0.0048244963,50.0,0.0048244963,-0.19180888,-1.6148162
Processing of Intronless Pre-mRNAs,0.00216962,15.0,0.00216962,-0.23238996,-0.2637663
Processing of SMDT1,0.069887646,9.0,0.069887646,0.802713,0.7477271
Processive synthesis on the lagging strand,0.044382416,11.0,0.044382416,0.41285315,0.37701496
Prolactin receptor signaling,0.0014867507,10.0,0.0014867507,-0.24282797,-0.0742323
Proline catabolism,1.7210756e-05,2.0,1.7210756e-05,-0.2652906,0.22470984
Propionyl-CoA catabolism,0.0069535417,5.0,0.0069535417,-0.1592654,0.18565235
Prostacyclin signalling through prostacyclin receptor,0.07835171,15.0,0.07835171,0.9320904,0.6077391
Protein methylation,0.0008399154,9.0,0.0008399154,-0.25271514,-0.04216278
Protein repair,0.035011098,4.0,0.035011098,0.269608,0.5460934
Proton-coupled monocarboxylate transport,0.0035875544,3.0,0.0035875544,-0.21071614,0.2260846
Proton-coupled neutral amino acid transporters,1.8106897e-08,2.0,1.8106897e-08,-0.26555339,0.22451319
Proton/oligopeptide cotransporters,0.00021065984,2.0,0.00021065984,-0.26233363,0.22692287
Purine ribonucleoside monophosphate biosynthesis,0.01126413,8.0,0.01126413,-0.093375966,0.11655698
Purine salvage,0.011521674,10.0,0.011521674,-0.08943927,0.04056488
Pyrimidine biosynthesis,0.002744544,3.0,0.002744544,-0.22360197,0.21644077
Pyrimidine catabolism,0.00012601985,4.0,0.00012601985,-0.2636274,0.14701626
Pyrimidine salvage,0.02048361,6.0,0.02048361,0.047548268,0.30096403
Pyrophosphate hydrolysis,0.00061211316,2.0,0.00061211316,-0.2561972,0.2315154
RA biosynthesis pathway,2.4419407e-05,14.0,2.4419407e-05,-0.2651804,-0.2488377
RAB GEFs exchange GTP for GDP on RABs,0.000351982,66.0,0.000351982,-0.26017344,-2.2974873
RAB geranylgeranylation,0.0013138562,49.0,0.0013138562,-0.24547073,-1.6155078
RAF activation,0.0009857131,19.0,0.0009857131,-0.25048655,-0.4351866
RAS signaling downstream of NF1 loss-of-function variants,0.0005571797,5.0,0.0005571797,-0.2570369,0.11247948
RET signaling,0.0035073822,24.0,0.0035073822,-0.21194161,-0.60368514
RHO GTPases Activate Formins,0.018338226,71.0,0.018338226,0.014755038,-2.2890747
RHO GTPases Activate NADPH Oxidases,7.6830685e-05,5.0,7.6830685e-05,-0.26437926,0.10698437
RHO GTPases Activate ROCKs,0.00021007193,14.0,0.00021007193,-0.2623426,-0.24671388
RHO GTPases Activate Rhotekin and Rhophilins,2.7904669e-06,6.0,2.7904669e-06,-0.265511,0.066668205
RHO GTPases Activate WASPs and WAVEs,0.0050457586,30.0,0.0050457586,-0.1884268,-0.8229015
RHO GTPases activate CIT,0.00021747932,11.0,0.00021747932,-0.26222938,-0.12822165
RHO GTPases activate IQGAPs,0.0032788366,12.0,0.0032788366,-0.21543504,-0.13266961
RHO GTPases activate KTN1,0.00226772,11.0,0.00226772,-0.23089045,-0.10476737
RHO GTPases activate PAKs,0.00049407984,16.0,0.00049407984,-0.25800142,-0.32240322
RHO GTPases regulate CFTR trafficking,0.00033419658,2.0,0.00033419658,-0.26044533,0.22833608
RIP-mediated NFkB activation via ZBP1,0.00080705,10.0,0.00080705,-0.2532175,-0.08200791
RMTs methylate histone arginines,0.009584398,27.0,0.009584398,-0.11905148,-0.652573
RNA Pol II CTD phosphorylation and interaction with CE,0.02637022,22.0,0.02637022,0.13752797,-0.2632012
RNA Polymerase I Chain Elongation,3.179075e-05,20.0,3.179075e-05,-0.2650677,-0.4855684
RNA Polymerase I Promoter Escape,0.023604302,20.0,0.023604302,0.09524957,-0.21590436
RNA Polymerase I Promoter Opening,0.00033265643,3.0,0.00033265643,-0.26046884,0.18884933
RNA Polymerase I Transcription Initiation,0.011445089,22.0,0.011445089,-0.09060991,-0.43394125
RNA Polymerase I Transcription Termination,0.0005239196,21.0,0.0005239196,-0.2575453,-0.51940775
RNA Polymerase II Pre-transcription Events,0.0791328,64.0,0.0791328,0.9440297,-1.3173147
RNA Polymerase II Promoter Escape,0.002864193,37.0,0.002864193,-0.22177307,-1.1241423
RNA Polymerase II Transcription Initiation,0.37571013,37.0,0.37571013,5.4773583,3.1411283
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening,0.18504481,37.0,0.18504481,2.5629463,0.95996153
RNA Polymerase III Abortive And Retractive Initiation,0.0006298929,27.0,0.0006298929,-0.25592545,-0.7550104
RNA Polymerase III Chain Elongation,0.00040290135,14.0,0.00040290135,-0.25939512,-0.24450795
RNA Polymerase III Transcription Initiation From Type 1 Promoter,0.00020061669,21.0,0.00020061669,-0.26248714,-0.5231063
RNA Polymerase III Transcription Initiation From Type 2 Promoter,3.0177465e-05,21.0,3.0177465e-05,-0.2650924,-0.525056
RNA Polymerase III Transcription Initiation From Type 3 Promoter,4.2485415e-05,21.0,4.2485415e-05,-0.26490426,-0.5249152
RNA Polymerase III Transcription Termination,0.0012620948,14.0,0.0012620948,-0.24626192,-0.23467898
RNA polymerase II transcribes snRNA genes,0.14583343,50.0,0.14583343,1.9635812,-0.0017066518
RNF mutants show enhanced WNT signaling and proliferation,0.0011838337,5.0,0.0011838337,-0.24745819,0.11964823
ROBO receptors bind AKAP5,6.7202454e-05,5.0,6.7202454e-05,-0.26452643,0.10687424
RORA activates gene expression,5.4230994e-05,4.0,5.4230994e-05,-0.2647247,0.14619502
"ROS, RNS production in phagocytes",0.006179201,16.0,0.006179201,-0.17110157,-0.25736678
RPIA deficiency: failed conversion of R5P to RU5P,0.0,1.0,0.0,-0.26555365,0.26398215
RPIA deficiency: failed conversion of RU5P to R5P,0.0,1.0,0.0,-0.26555365,0.26398215
RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs),0.00036391924,5.0,0.00036391924,-0.25999096,0.110268615
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known,0.003706108,29.0,0.003706108,-0.208904,-0.7987576
RUNX1 regulates estrogen receptor mediated transcription,0.00043805168,7.0,0.00043805168,-0.25885785,0.032178313
RUNX1 regulates expression of components of tight junctions,0.00029623866,4.0,0.00029623866,-0.26102552,0.14896353
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,0.0029140247,29.0,0.0029140247,-0.22101139,-0.80781883
RUNX1 regulates transcription of genes involved in BCR signaling,0.001928696,6.0,0.001928696,-0.2360726,0.088700116
RUNX1 regulates transcription of genes involved in WNT signaling,7.702161e-05,6.0,7.702161e-05,-0.26437634,0.06751741
RUNX1 regulates transcription of genes involved in differentiation of HSCs,0.00024231046,48.0,0.00024231046,-0.26184985,-1.588297
RUNX1 regulates transcription of genes involved in differentiation of keratinocytes,0.0002499391,7.0,0.0002499391,-0.26173323,0.030026363
RUNX1 regulates transcription of genes involved in differentiation of myeloid cells,0.00033807836,6.0,0.00033807836,-0.260386,0.0705038
RUNX1 regulates transcription of genes involved in interleukin signaling,0.0005439347,6.0,0.0005439347,-0.25723934,0.072858766
RUNX2 regulates bone development,0.009824649,23.0,0.009824649,-0.11537912,-0.49194792
RUNX2 regulates genes involved in cell migration,0.0023353952,7.0,0.0023353952,-0.229856,0.053883493
RUNX2 regulates genes involved in differentiation of myeloid cells,0.00033489277,4.0,0.00033489277,-0.26043466,0.14940572
RUNX3 Regulates Immune Response and Cell Migration,0.0009398515,3.0,0.0009398515,-0.25118756,0.19579549
RUNX3 regulates BCL2L11 (BIM) transcription,0.0005104668,4.0,0.0005104668,-0.25775093,0.15141425
RUNX3 regulates CDKN1A transcription,0.0013398037,6.0,0.0013398037,-0.2450741,0.08196332
RUNX3 regulates NOTCH signaling,0.005962929,11.0,0.005962929,-0.1744074,-0.062495038
RUNX3 regulates RUNX1-mediated transcription,7.2462663e-06,3.0,7.2462663e-06,-0.2654429,0.18512669
RUNX3 regulates WNT signaling,0.013813353,8.0,0.013813353,-0.054409843,0.1457195
RUNX3 regulates YAP1-mediated transcription,0.0016036072,4.0,0.0016036072,-0.24104175,0.16391952
RUNX3 regulates p14-ARF,0.007464296,6.0,0.007464296,-0.15145826,0.15202609
Rap1 signalling,0.015033201,9.0,0.015033201,-0.035763867,0.1202051
Receptor Mediated Mitophagy,0.009269021,11.0,0.009269021,-0.12387216,-0.024674106
Receptor-type tyrosine-protein phosphatases,0.009176809,12.0,0.009176809,-0.12528166,-0.06519817
Recognition and association of DNA glycosylase with site containing an affected purine,1.3298919e-08,3.0,1.3298919e-08,-0.26555347,0.18504395
Recognition and association of DNA glycosylase with site containing an affected pyrimidine,0.006127602,8.0,0.006127602,-0.17189029,0.0577963
Recognition of DNA damage by PCNA-containing replication complex,0.04552244,22.0,0.04552244,0.430279,-0.044104286
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.006330852,34.0,0.006330852,-0.16878352,-0.966077
Recruitment of NuMA to mitotic centrosomes,0.009957169,58.0,0.009957169,-0.11335349,-1.8718529
Recycling of bile acids and salts,0.022714399,8.0,0.022714399,0.08164697,0.24754539
Recycling of eIF2:GDP,0.21131766,8.0,0.21131766,2.9645393,2.4051228
Recycling pathway of L1,0.0013586291,21.0,0.0013586291,-0.24478637,-0.50985885
Reduction of cytosolic Ca++ levels,0.0030430087,7.0,0.0030430087,-0.21903978,0.061978426
Reelin signalling pathway,0.00035247082,5.0,0.00035247082,-0.260166,0.110137634
Regulated proteolysis of p75NTR,0.00013362314,10.0,0.00013362314,-0.26351118,-0.089711785
Regulation by TREX1,0.0,1.0,0.0,-0.26555365,0.26398215
Regulation by c-FLIP,0.006504029,9.0,0.006504029,-0.16613641,0.022633359
Regulation of Complement cascade,0.0005322437,16.0,0.0005322437,-0.25741807,-0.32196665
Regulation of FZD by ubiquitination,0.001266608,14.0,0.001266608,-0.24619295,-0.23462734
Regulation of Glucokinase by Glucokinase Regulatory Protein,0.014903834,25.0,0.014903834,-0.03774131,-0.51278156
Regulation of HSF1-mediated heat shock response,0.006876168,49.0,0.006876168,-0.16044809,-1.5518762
Regulation of IFNA signaling,0.002224727,15.0,0.002224727,-0.23154764,-0.26313588
Regulation of IFNG signaling,1.3711966e-06,11.0,1.3711966e-06,-0.2655327,-0.13069387
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0029399842,70.0,0.0029399842,-0.22061457,-2.4257581
Regulation of KIT signaling,0.0785111,12.0,0.0785111,0.9345266,0.72796994
Regulation of PAK-2p34 activity by PS-GAP/RHG10,0.0005372769,3.0,0.0005372769,-0.25734115,0.19119012
Regulation of PLK1 Activity at G2/M Transition,0.01751537,61.0,0.01751537,0.0021772962,-1.9037963
Regulation of PTEN gene transcription,0.05367614,40.0,0.05367614,0.5549122,-0.66127294
Regulation of PTEN localization,0.052713167,8.0,0.052713167,0.5401927,0.5907243
Regulation of PTEN mRNA translation,0.00085746945,10.0,0.00085746945,-0.25244683,-0.081431136
Regulation of PTEN stability and activity,0.20913805,49.0,0.20913805,2.9312232,0.7619525
Regulation of RAS by GAPs,0.0032094987,47.0,0.0032094987,-0.21649492,-1.5148838
Regulation of RUNX1 Expression and Activity,0.00129247,17.0,0.00129247,-0.24579762,-0.352739
Regulation of RUNX2 expression and activity,0.0012425671,47.0,0.0012425671,-0.24656042,-1.5373851
Regulation of RUNX3 expression and activity,0.0006499579,34.0,0.0006499579,-0.25561872,-1.0310651
Regulation of TLR by endogenous ligand,0.033302907,8.0,0.033302907,0.24349746,0.36867547
Regulation of TNFR1 signaling,0.0036651941,22.0,0.0036651941,-0.20952938,-0.52294147
Regulation of TP53 Activity,0.007905165,122.0,6.479643e-05,-0.26456323,-4.4213543
Regulation of actin dynamics for phagocytic cup formation,0.02786985,45.0,0.02786985,0.16045055,-1.1538367
Regulation of activated PAK-2p34 by proteasome mediated degradation,0.003401291,33.0,0.003401291,-0.21356328,-0.9601213
Regulation of commissural axon pathfinding by SLIT and ROBO,0.00018583507,6.0,0.00018583507,-0.2627131,0.068762176
Regulation of cortical dendrite branching,6.880939e-06,3.0,6.880939e-06,-0.26544848,0.18512252
Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,0.0065762307,6.0,0.0065762307,-0.16503277,0.14186682
Regulation of expression of SLITs and ROBOs,0.0006235587,88.0,0.0006235587,-0.25602224,-3.1627023
Regulation of gene expression by Hypoxia-inducible Factor,0.0017079129,7.0,0.0017079129,-0.23944737,0.04670524
Regulation of gene expression in early pancreatic precursor cells,8.9238405e-08,2.0,8.9238405e-08,-0.26555228,0.22451398
Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells,5.4707084e-07,3.0,5.4707084e-07,-0.26554528,0.18505007
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells,4.6982263e-06,4.0,4.6982263e-06,-0.26548186,0.14562836
Regulation of ornithine decarboxylase (ODC),0.01996023,34.0,0.01996023,0.039548162,-0.81016004
Regulation of pyruvate dehydrogenase (PDH) complex,0.04568426,10.0,0.04568426,0.43275246,0.4313769
Regulation of signaling by CBL,2.4250858e-05,18.0,2.4250858e-05,-0.26518297,-0.40671632
Regulation of signaling by NODAL,7.602099e-05,7.0,7.602099e-05,-0.26439166,0.028036758
Regulation of thyroid hormone activity,0.002179826,2.0,0.002179826,-0.23223397,0.24944966
Release of Hh-Np from the secreting cell,0.00013491458,5.0,0.00013491458,-0.26349142,0.10764886
Release of apoptotic factors from the mitochondria,0.0016537468,3.0,0.0016537468,-0.24027532,0.20396231
Removal of aminoterminal propeptides from gamma-carboxylated proteins,0.0013173403,6.0,0.0013173403,-0.24541746,0.08170635
Repression of WNT target genes,0.0026955055,9.0,0.0026955055,-0.22435156,-0.020935263
Resolution of Sister Chromatid Cohesion,0.01255346,60.0,0.01255346,-0.07366792,-1.9210902
Retinoid metabolism and transport,0.0065994784,27.0,0.0065994784,-0.16467743,-0.6867198
Retinoid metabolism disease events,0.0,1.0,0.0,-0.26555365,0.26398215
Retrograde neurotrophin signalling,0.12987342,11.0,0.12987342,1.7196248,1.3550122
Retrograde transport at the Trans-Golgi-Network,0.0003798573,41.0,0.0003798573,-0.25974736,-1.3104391
Reuptake of GABA,0.0,1.0,0.0,-0.26555365,0.26398215
Reversible hydration of carbon dioxide,5.9889786e-05,7.0,5.9889786e-05,-0.26463822,0.027852224
Rhesus glycoproteins mediate ammonium transport.,1.2701817e-07,2.0,1.2701817e-07,-0.26555172,0.22451441
Rho GTPase cycle,0.014679918,86.0,0.014679918,-0.041163974,-2.9229624
Ribosomal scanning and start codon recognition,0.18247952,31.0,0.18247952,2.5237346,1.1674302
Role of ABL in ROBO-SLIT signaling,2.3922816e-05,8.0,2.3922816e-05,-0.265188,-0.012028388
Role of LAT2/NTAL/LAB on calcium mobilization,0.0038494735,11.0,0.0038494735,-0.20671259,-0.08667247
Role of phospholipids in phagocytosis,0.0030873849,14.0,0.0030873849,-0.21836148,-0.21379809
Role of second messengers in netrin-1 signaling,0.0012683714,8.0,0.0012683714,-0.24616598,0.0022078392
S33 mutants of beta-catenin aren't phosphorylated,0.00054264773,12.0,0.00054264773,-0.257259,-0.16397096
S37 mutants of beta-catenin aren't phosphorylated,5.668286e-05,12.0,5.668286e-05,-0.26468724,-0.16953029
S45 mutants of beta-catenin aren't phosphorylated,0.0020990765,12.0,0.0020990765,-0.23346826,-0.14616579
SCF(Skp2)-mediated degradation of p27/p21,0.027374743,40.0,0.027374743,0.15288259,-0.9621548
SDK interactions,0.0,1.0,0.0,-0.26555365,0.26398215
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion,0.0009124462,8.0,0.0009124462,-0.25160646,-0.001863861
SHC-related events triggered by IGF1R,0.0045309276,6.0,0.0045309276,-0.19629623,0.11846903
SHC1 events in EGFR signaling,0.052257687,6.0,0.052257687,0.5332305,0.664452
SHC1 events in ERBB2 signaling,0.13778211,15.0,0.13778211,1.8405129,1.2876091
SHC1 events in ERBB4 signaling,0.033743333,9.0,0.033743333,0.2502296,0.33424467
SIRT1 negatively regulates rRNA expression,0.036330584,7.0,0.036330584,0.28977698,0.44278055
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs,0.017309703,7.0,0.017309703,-0.0009664344,0.22518608
SLBP independent Processing of Histone Pre-mRNAs,0.0009141585,7.0,0.0009141585,-0.2515803,0.037624866
SLIT2:ROBO1 increases RHOA activity,5.1909205e-06,3.0,5.1909205e-06,-0.26547432,0.18510318
SMAC-mediated apoptotic response,0.0039204485,6.0,0.0039204485,-0.2056277,0.1114853
SMAD2/3 MH2 Domain Mutants in Cancer,0.001066934,7.0,0.001066934,-0.24924505,0.039372586
SMAD2/3 Phosphorylation Motif Mutants in Cancer,0.003040483,6.0,0.003040483,-0.21907839,0.101418704
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,0.007115936,25.0,0.007115936,-0.15678312,-0.6018733
SMAD4 MH2 Domain Mutants in Cancer,0.0003870227,4.0,0.0003870227,-0.25963783,0.15000206
SRP-dependent cotranslational protein targeting to membrane,0.015249313,51.0,0.015249313,-0.0324605,-1.5350279
STAT6-mediated induction of chemokines,6.901552e-06,3.0,6.901552e-06,-0.26544818,0.18512273
SUMO is conjugated to E1 (UBA2:SAE1),0.010742691,4.0,0.010742691,-0.1013464,0.26846853
SUMO is proteolytically processed,0.0015360728,7.0,0.0015360728,-0.24207404,0.04473943
"SUMO is transferred from E1 to E2 (UBE2I, UBC9)",0.012953932,5.0,0.012953932,-0.0675465,0.25429544
SUMOylation of DNA damage response and repair proteins,0.0016810216,57.0,0.0016810216,-0.23985842,-1.9270608
SUMOylation of DNA methylation proteins,0.00019525542,10.0,0.00019525542,-0.2625691,-0.08900671
SUMOylation of DNA replication proteins,0.00020285252,34.0,0.00020285252,-0.26245296,-1.0361799
SUMOylation of RNA binding proteins,9.52151e-05,35.0,9.52151e-05,-0.26409826,-1.0768803
SUMOylation of SUMOylation proteins,0.00017882767,29.0,0.00017882767,-0.2628202,-0.8391089
SUMOylation of chromatin organization proteins,0.00044502856,41.0,0.00044502856,-0.25875118,-1.3096936
SUMOylation of immune response proteins,0.00035854176,11.0,0.00035854176,-0.26007316,-0.12660792
SUMOylation of intracellular receptors,0.00020057251,21.0,0.00020057251,-0.2624878,-0.5231067
SUMOylation of transcription cofactors,0.00016634207,34.0,0.00016634207,-0.26301104,-1.0365975
SUMOylation of transcription factors,0.00015261493,19.0,0.00015261493,-0.26322085,-0.44471705
SUMOylation of ubiquitinylation proteins,0.0001806422,32.0,0.0001806422,-0.26279244,-0.95749557
Scavenging by Class A Receptors,0.02074508,11.0,0.02074508,0.051544975,0.10660933
Scavenging by Class B Receptors,0.0016900914,3.0,0.0016900914,-0.2397198,0.20437805
Scavenging by Class F Receptors,0.0048668496,5.0,0.0048668496,-0.1911615,0.16178107
Scavenging by Class H Receptors,0.05651647,3.0,0.05651647,0.59832805,0.83157897
Scavenging of heme from plasma,0.009008577,8.0,0.009008577,-0.12785318,0.09075398
SeMet incorporation into proteins,0.0042688875,4.0,0.0042688875,-0.20030165,0.19440971
Selenocysteine synthesis,0.00011029213,36.0,0.00011029213,-0.2638678,-1.116177
Sema3A PAK dependent Axon repulsion,0.00015324622,11.0,0.00015324622,-0.26321122,-0.12895647
Sema4D induced cell migration and growth-cone collapse,6.998803e-05,15.0,6.998803e-05,-0.26448384,-0.28778556
Sema4D mediated inhibition of cell attachment and migration,5.3136426e-07,6.0,5.3136426e-07,-0.26554555,0.06664235
Senescence-Associated Secretory Phenotype (SASP),0.021883335,33.0,0.021883335,0.068943754,-0.748691
Sensing of DNA Double Strand Breaks,0.0005767208,5.0,0.0005767208,-0.2567382,0.11270301
Serine biosynthesis,0.008325074,8.0,0.008325074,-0.13830087,0.082934864
Serotonin Neurotransmitter Release Cycle,8.717152e-05,9.0,8.717152e-05,-0.2642212,-0.05077399
Serotonin and melatonin biosynthesis,0.00028560814,3.0,0.00028560814,-0.261188,0.18831111
Severe congenital neutropenia type 4 (G6PC3),0.0,1.0,0.0,-0.26555365,0.26398215
Signal attenuation,0.029988088,7.0,0.029988088,0.19282885,0.37022385
Signal regulatory protein family interactions,7.98107e-05,8.0,7.98107e-05,-0.26433372,-0.011389014
Signal transduction by L1,0.0030130765,14.0,0.0030130765,-0.21949732,-0.21464816
Signaling by BMP,0.006975181,18.0,0.006975181,-0.15893462,-0.32719928
Signaling by BRAF and RAF fusions,0.0054323166,43.0,0.0054323166,-0.18251805,-1.3315785
Signaling by FGFR3 fusions in cancer,0.001950174,9.0,0.001950174,-0.23574431,-0.029461687
Signaling by FGFR3 point mutants in cancer,0.005828381,16.0,0.005828381,-0.17646404,-0.26138008
Signaling by Hippo,0.042990044,14.0,0.042990044,0.39157006,0.24267903
Signaling by Leptin,0.048024535,10.0,0.048024535,0.46852472,0.4581491
Signaling by MST1,0.017604427,2.0,0.017604427,0.0035385725,0.42590347
Signaling by RAS mutants,0.023246577,37.0,0.023246577,0.089781575,-0.89097255
Signaling by high-kinase activity BRAF mutants,0.022454778,22.0,0.022454778,0.07767854,-0.30799296
Signaling by moderate kinase activity BRAF mutants,0.0008531374,28.0,0.0008531374,-0.25251302,-0.7919258
Signalling to ERK5,0.007730279,3.0,0.007730279,-0.14739259,0.27347642
Signalling to ERKs,0.026919888,22.0,0.026919888,0.14592992,-0.25691316
Signalling to STAT3,0.034947634,3.0,0.034947634,0.26863793,0.58483654
Small interfering RNA (siRNA) biogenesis,0.00024748815,7.0,0.00024748815,-0.2617707,0.029998323
Smooth Muscle Contraction,0.041600306,22.0,0.041600306,0.37032723,-0.0889726
"Sodium-coupled sulphate, di- and tri-carboxylate transporters",0.00010952164,3.0,0.00010952164,-0.26387957,0.18629669
Sodium/Calcium exchangers,0.00023307581,7.0,0.00023307581,-0.26199096,0.029833457
Sodium/Proton exchangers,8.227117e-06,9.0,8.227117e-06,-0.26542792,-0.051677108
Sperm Motility And Taxes,0.00014466929,6.0,0.00014466929,-0.26334232,0.06829126
Sperm:Oocyte Membrane Binding,0.0012572582,3.0,0.0012572582,-0.24633586,0.19942655
Sphingolipid de novo biosynthesis,0.019874439,23.0,0.019874439,0.038236797,-0.37698066
Stimulation of the cell death response by PAK-2p34,0.00077342574,3.0,0.00077342574,-0.25373146,0.19389163
Striated Muscle Contraction,0.019001447,27.0,0.019001447,0.024892692,-0.54484415
Sulfide oxidation to sulfate,0.0001107884,2.0,0.0001107884,-0.2638602,0.22578034
Surfactant metabolism,0.00019030739,12.0,0.00019030739,-0.26264474,-0.16800167
Synaptic adhesion-like molecules,0.00045910044,17.0,0.00045910044,-0.25853607,-0.36227253
Syndecan interactions,0.00020584089,12.0,0.00020584089,-0.26240727,-0.16782397
Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE),0.002197012,7.0,0.002197012,-0.23197126,0.052300416
Synthesis of 12-eicosatetraenoic acid derivatives,0.0015883696,4.0,0.0015883696,-0.24127467,0.1637452
Synthesis of 15-eicosatetraenoic acid derivatives,0.0014027995,2.0,0.0014027995,-0.2441112,0.24056067
Synthesis of 5-eicosatetraenoic acids,0.044498384,5.0,0.044498384,0.41462576,0.6151566
Synthesis of BMP,0.0,1.0,0.0,-0.26555365,0.26398215
Synthesis of CL,8.0272024e-05,2.0,8.0272024e-05,-0.26432666,0.22543125
Synthesis of Hepoxilins (HX) and Trioxilins (TrX),9.757028e-05,2.0,9.757028e-05,-0.26406226,0.22562914
"Synthesis of IP2, IP, and Ins in the cytosol",0.018583775,12.0,0.018583775,0.01850837,0.04241533
Synthesis of IP3 and IP4 in the cytosol,0.015294621,18.0,0.015294621,-0.031767946,-0.23202683
Synthesis of IPs in the ER lumen,0.0,1.0,0.0,-0.26555365,0.26398215
Synthesis of IPs in the nucleus,0.003589841,4.0,0.003589841,-0.2106812,0.18664157
Synthesis of Ketone Bodies,0.003312854,5.0,0.003312854,-0.21491508,0.14400373
Synthesis of Leukotrienes (LT) and Eoxins (EX),0.029742835,11.0,0.029742835,0.18908003,0.20954156
Synthesis of Lipoxins (LX),0.005740476,3.0,0.005740476,-0.1778077,0.25071353
Synthesis of PA,0.00040743235,22.0,0.00040743235,-0.25932586,-0.5602095
Synthesis of PC,0.0051850486,19.0,0.0051850486,-0.18629767,-0.38714716
Synthesis of PE,0.010209887,11.0,0.010209887,-0.109490566,-0.0139108235
Synthesis of PG,0.0035855558,7.0,0.0035855558,-0.2107467,0.06818503
Synthesis of PI,0.0030666015,6.0,0.0030666015,-0.21867917,0.10171748
Synthesis of PIPs at the ER membrane,0.05225149,6.0,0.05225149,0.5331358,0.6643812
Synthesis of PIPs at the Golgi membrane,0.13809434,13.0,0.13809434,1.8452854,1.3701192
Synthesis of PIPs at the early endosome membrane,0.37698343,14.0,0.37698343,5.4968214,4.0634856
Synthesis of PIPs at the late endosome membrane,0.004110022,10.0,0.004110022,-0.20272999,-0.044222698
Synthesis of PIPs at the plasma membrane,0.15364535,44.0,0.15364535,2.0829904,0.32447496
Synthesis of PIPs in the nucleus,0.077172115,4.0,0.077172115,0.91405964,1.0284057
Synthesis of PS,0.0,1.0,0.0,-0.26555365,0.26398215
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),0.015066207,9.0,0.015066207,-0.035259355,0.120582685
Synthesis of active ubiquitin: roles of E1 and E2 enzymes,0.00060878426,23.0,0.00060878426,-0.2562481,-0.5973753
Synthesis of bile acids and bile salts,0.030641897,15.0,0.030641897,0.20282263,0.06194993
Synthesis of diphthamide-EEF2,0.009102955,8.0,0.009102955,-0.12641056,0.09183365
Synthesis of dolichyl-phosphate mannose,2.9471876e-06,2.0,2.9471876e-06,-0.26550862,0.22454667
Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET),2.4036219e-05,5.0,2.4036219e-05,-0.26518628,0.106380425
Synthesis of glycosylphosphatidylinositol (GPI),8.973157e-05,13.0,8.973157e-05,-0.2641821,-0.2086214
Synthesis of pyrophosphates in the cytosol,0.026636675,6.0,0.026636675,0.14160086,0.37135366
Synthesis of very long-chain fatty acyl-CoAs,0.058400594,14.0,0.058400594,0.6271278,0.41897213
Synthesis of wybutosine at G37 of tRNA(Phe),1.5243195e-05,3.0,1.5243195e-05,-0.26532066,0.1852182
"Synthesis, secretion, and deacylation of Ghrelin",0.023308307,7.0,0.023308307,0.090725146,0.29380873
"Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)",0.0004047674,8.0,0.0004047674,-0.2593666,-0.007671582
"Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)",0.00029765855,8.0,0.00029765855,-0.26100382,-0.008896908
T41 mutants of beta-catenin aren't phosphorylated,0.00011617267,12.0,0.00011617267,-0.2637779,-0.16884974
TAK1 activates NFkB by phosphorylation and activation of IKKs complex,0.0043760254,17.0,0.0043760254,-0.19866398,-0.31746385
"TALDO1 deficiency: failed conversion of  Fru(6)P, E4P to SH7P, GA3P",0.0,1.0,0.0,-0.26555365,0.26398215
"TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P",0.0,1.0,0.0,-0.26555365,0.26398215
TBC/RABGAPs,0.0010502209,30.0,0.0010502209,-0.24950053,-0.8686095
TCF7L2 mutants don't bind CTBP,9.388865e-05,3.0,9.388865e-05,-0.26411852,0.18611786
"TET1,2,3 and TDG demethylate DNA",0.00030336846,4.0,0.00030336846,-0.26091653,0.14904511
TFAP2 (AP-2) family regulates transcription of cell cycle factors,0.0049520666,5.0,0.0049520666,-0.18985891,0.16275595
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,0.0011784658,9.0,0.0011784658,-0.24754024,-0.038289856
TFAP2 (AP-2) family regulates transcription of other transcription factors,0.00018695685,2.0,0.00018695685,-0.26269594,0.22665171
TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation,0.0013843375,4.0,0.0013843375,-0.24439338,0.16141114
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition),0.044457223,13.0,0.044457223,0.4139966,0.2989324
TGFBR1 KD Mutants in Cancer,0.00015085185,6.0,0.00015085185,-0.26324782,0.06836198
TGFBR1 LBD Mutants in Cancer,0.0005391333,3.0,0.0005391333,-0.25731274,0.19121137
TGFBR2 Kinase Domain Mutants in Cancer,0.00028619872,3.0,0.00028619872,-0.26117897,0.18831785
TGFBR2 MSI Frameshift Mutants in Cancer,2.2565325e-06,2.0,2.2565325e-06,-0.26551917,0.22453876
TICAM1 deficiency - HSE,0.0023169375,2.0,0.0023169375,-0.23013814,0.25101817
"TICAM1, RIP1-mediated IKK complex recruitment ",0.023946041,14.0,0.023946041,0.100473225,0.02482007
"TICAM1,TRAF6-dependent induction of TAK1 complex",0.012514706,11.0,0.012514706,-0.074260294,0.012455765
TICAM1-dependent activation of IRF3/IRF7,3.9256593e-06,10.0,3.9256593e-06,-0.26549363,-0.09119547
TLR3 deficiency - HSE,0.0006801173,2.0,0.0006801173,-0.25515774,0.23229334
TLR3-mediated TICAM1-dependent programmed cell death,0.0043464666,6.0,0.0043464666,-0.1991158,0.116358854
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway,0.016734323,9.0,0.016734323,-0.009761403,0.13966553
TNFR1-induced NFkappaB signaling pathway,0.00016951168,12.0,0.00016951168,-0.26296258,-0.16823956
TNFR1-induced proapoptotic signaling,0.00015077497,4.0,0.00015077497,-0.26324898,0.14729945
TNFR1-mediated ceramide production,0.0014699203,2.0,0.0014699203,-0.24308522,0.2413285
TNFs bind their physiological receptors,0.009781079,9.0,0.009781079,-0.11604511,0.060122043
TP53 Regulates Metabolic Genes,0.004880817,54.0,0.004880817,-0.190948,-1.7720486
TP53 Regulates Transcription of Cell Cycle Genes,0.002441951,29.0,0.002441951,-0.22822726,-0.81321925
TP53 Regulates Transcription of Cell Death Genes,0.0025404368,31.0,0.0025404368,-0.22672185,-0.89103097
TP53 Regulates Transcription of DNA Repair Genes,0.0002827146,49.0,0.0002827146,-0.26123223,-1.6273037
TRAF3 deficiency - HSE,0.0006057194,3.0,0.0006057194,-0.25629494,0.19197309
TRAF3-dependent IRF activation pathway,6.0156188e-05,12.0,6.0156188e-05,-0.26463416,-0.16949056
TRAF6 mediated IRF7 activation,0.0008959544,18.0,0.0008959544,-0.25185856,-0.39674425
TRAF6 mediated NF-kB activation,0.002422939,14.0,0.002422939,-0.22851786,-0.22139917
TRAIL  signaling,0.0012233757,7.0,0.0012233757,-0.24685377,0.041162252
TRP channels,0.02327748,11.0,0.02327748,0.09025394,0.13557939
TWIK related potassium channel (TREK),0.0,1.0,0.0,-0.26555365,0.26398215
TWIK-related alkaline pH activated K+ channel (TALK),0.0020898855,3.0,0.0020898855,-0.23360874,0.2089516
TWIK-related spinal cord K+ channel (TRESK),3.0411508e-07,2.0,3.0411508e-07,-0.26554903,0.22451644
TWIK-releated acid-sensitive K+ channel (TASK),0.0,1.0,0.0,-0.26555365,0.26398215
TYSND1 cleaves peroxisomal proteins,0.018072622,6.0,0.018072622,0.010695153,0.27338287
Tandem of pore domain in a weak inwardly rectifying K+ channels (TWIK),0.009427608,3.0,0.009427608,-0.12144809,0.29289347
Tandem pore domain halothane-inhibited K+ channel (THIK),0.0,1.0,0.0,-0.26555365,0.26398215
Telomere C-strand (Lagging Strand) Synthesis,0.006055286,17.0,0.006055286,-0.17299567,-0.29825348
Telomere Extension By Telomerase,0.035436254,3.0,0.035436254,0.27610672,0.59042627
Terminal pathway of complement,5.407506e-06,4.0,5.407506e-06,-0.265471,0.14563648
Termination of O-glycan biosynthesis,0.0070440685,10.0,0.0070440685,-0.15788165,-0.010657876
Termination of translesion DNA synthesis,0.022259593,22.0,0.022259593,0.07469504,-0.31022584
"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",0.0057957154,8.0,0.0057957154,-0.17696333,0.05399959
The AIM2 inflammasome,4.6188193e-06,2.0,4.6188193e-06,-0.26548305,0.2245658
The IPAF inflammasome,0.00032400872,3.0,0.00032400872,-0.260601,0.18875039
The NLRP1 inflammasome,0.005939242,3.0,0.005939242,-0.17476946,0.25298735
The NLRP3 inflammasome,0.03687662,9.0,0.03687662,0.2981234,0.3700887
The activation of arylsulfatases,0.007375826,6.0,0.007375826,-0.15281057,0.15101402
The fatty acid cycling model,0.00023995548,3.0,0.00023995548,-0.26188582,0.18778884
The proton buffering model,0.0021590665,3.0,0.0021590665,-0.23255128,0.20974302
The role of GTSE1 in G2/M progression after G2 checkpoint,0.008121711,37.0,0.008121711,-0.14140935,-1.0639975
The role of Nef in HIV-1 replication and disease pathogenesis,0.011852456,24.0,0.011852456,-0.0843831,-0.5082194
Threonine catabolism,0.001319996,3.0,0.001319996,-0.2453769,0.20014423
Thrombin signalling through proteinase activated receptors (PARs),0.02166397,24.0,0.02166397,0.06559064,-0.395978
Thromboxane signalling through TP receptor,0.025627386,18.0,0.025627386,0.12617339,-0.11382241
Tie2 Signaling,0.0017421918,12.0,0.0017421918,-0.23892342,-0.15024847
Tight junction interactions,0.003656312,18.0,0.003656312,-0.20966515,-0.36516637
Tolerance by Mtb to nitric oxide produced by macrophages,0.0,1.0,0.0,-0.26555365,0.26398215
Tolerance of reactive oxygen produced by macrophages,0.0,1.0,0.0,-0.26555365,0.26398215
Toxicity of botulinum toxin type A (BoNT/A),0.009276701,3.0,0.009276701,-0.12375477,0.2911671
Toxicity of botulinum toxin type B (BoNT/B),5.4084476e-10,2.0,5.4084476e-10,-0.26555365,0.22451296
Toxicity of botulinum toxin type C (BoNT/C),0.00056415464,4.0,0.00056415464,-0.2569303,0.15202841
Toxicity of botulinum toxin type D (BoNT/D),0.008512769,4.0,0.008512769,-0.13543186,0.24295871
Toxicity of botulinum toxin type E (BoNT/E),0.029818257,3.0,0.029818257,0.1902329,0.52615774
Toxicity of botulinum toxin type F (BoNT/F),4.120481e-06,4.0,4.120481e-06,-0.26549068,0.14562175
Toxicity of botulinum toxin type G (BoNT/G),0.007079593,3.0,0.007079593,-0.15733863,0.2660327
Toxicity of tetanus toxin (TeNT),2.3847685e-10,2.0,2.3847685e-10,-0.26555365,0.22451296
Trafficking and processing of endosomal TLR,0.0051400615,9.0,0.0051400615,-0.18698533,0.0070298878
Trafficking of AMPA receptors,0.00029222106,19.0,0.00029222106,-0.2610869,-0.44311997
Trafficking of myristoylated proteins to the cilium,0.0023138025,6.0,0.0023138025,-0.23018607,0.09310564
Transcription of E2F targets under negative control by DREAM complex,0.0060382495,12.0,0.0060382495,-0.17325608,-0.10110256
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1,0.003897052,6.0,0.003897052,-0.20598532,0.111217655
Transcriptional Regulation by E2F6,0.00012201874,23.0,0.00012201874,-0.26368856,-0.6029438
Transcriptional activation of mitochondrial biogenesis,0.0008006032,22.0,0.0008006032,-0.25331604,-0.5557117
Transcriptional regulation by small RNAs,0.0021891259,35.0,0.0021891259,-0.23209181,-1.0529265
Transcriptional regulation of white adipocyte differentiation,0.012402664,40.0,0.012402664,-0.075972915,-1.1334319
Transfer of LPS from LBP carrier to CD14,2.240279e-05,2.0,2.240279e-05,-0.26521122,0.22476925
Transferrin endocytosis and recycling,0.01677912,19.0,0.01677912,-0.009076665,-0.25451368
Translesion Synthesis by POLH,0.0029466113,12.0,0.0029466113,-0.22051327,-0.13647017
Translesion synthesis by POLI,0.00010062948,12.0,0.00010062948,-0.2640155,-0.16902755
Translesion synthesis by POLK,0.011953949,12.0,0.011953949,-0.08283174,-0.033428337
Translesion synthesis by REV1,0.0030349502,11.0,0.0030349502,-0.21916297,-0.09599043
Translocation of SLC2A4 (GLUT4) to the plasma membrane,6.781112e-06,39.0,6.781112e-06,-0.26545,-1.2357687
Translocation of ZAP-70 to Immunological synapse,0.00028815342,3.0,0.00028815342,-0.2611491,0.18834022
Transport and synthesis of PAPS,0.0083001135,5.0,0.0083001135,-0.1386824,0.20105682
Transport of Mature mRNA Derived from an Intronless Transcript,0.0031035282,11.0,0.0031035282,-0.21811472,-0.09520591
Transport of Mature mRNA derived from an Intron-Containing Transcript,0.05413797,62.0,0.05413797,0.56197155,-1.5243115
Transport of Ribonucleoproteins into the Host Nucleus,0.0025555796,3.0,0.0025555796,-0.22649038,0.21427904
Transport of fatty acids,0.00042671416,4.0,0.00042671416,-0.25903115,0.15045613
Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus,0.00017087547,5.0,0.00017087547,-0.26294175,0.10806023
Transport of glycerol from adipocytes to the liver by Aquaporins,0.0,1.0,0.0,-0.26555365,0.26398215
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane,0.0022634936,4.0,0.0022634936,-0.23095506,0.17146847
Transport of nucleotide sugars,0.004089616,9.0,0.004089616,-0.20304188,-0.00498697
Transport of organic anions,1.9718713e-05,5.0,1.9718713e-05,-0.26525226,0.10633102
Transport of the SLBP Dependant Mature mRNA,0.0062006335,6.0,0.0062006335,-0.17077395,0.1375701
Transport of the SLBP independent Mature mRNA,0.00061851955,6.0,0.00061851955,-0.25609928,0.073711984
Triglyceride biosynthesis,0.004387813,8.0,0.004387813,-0.19848381,0.03789352
Triglyceride catabolism,0.0025750794,18.0,0.0025750794,-0.22619233,-0.37753546
"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",0.013257304,11.0,0.013257304,-0.06290932,0.020950915
Truncations of AMER1 destabilize the destruction complex,0.0010419466,11.0,0.0010419466,-0.249627,-0.118789926
Tryptophan catabolism,0.00028389296,6.0,0.00028389296,-0.26121423,0.06988396
Type I hemidesmosome assembly,0.00041960063,4.0,0.00041960063,-0.25913987,0.15037476
Type II Na+/Pi cotransporters,3.4394034e-05,2.0,3.4394034e-05,-0.26502794,0.22490643
UCH proteinases,0.0034667861,62.0,0.0034667861,-0.21256216,-2.1039782
UNC93B1 deficiency - HSE,0.0010085248,2.0,0.0010085248,-0.25013787,0.23605026
Ub-specific processing proteases,0.002004257,121.0,1.6564107e-05,-0.26530045,-4.44939
Ubiquinol biosynthesis,0.035208307,5.0,0.035208307,0.27262244,0.5088803
Ubiquitin-dependent degradation of Cyclin D1,0.03464982,35.0,0.03464982,0.26408568,-0.68158376
"Unblocking of NMDA receptor, glutamate binding and activation",0.001394362,12.0,0.001394362,-0.24424016,-0.15422755
Unwinding of DNA,0.00014684447,9.0,0.00014684447,-0.26330906,-0.050091352
Uptake and function of anthrax toxins,0.035832018,7.0,0.035832018,0.28215614,0.43707705
Uptake and function of diphtheria toxin,0.0012452434,3.0,0.0012452434,-0.2465195,0.19928911
Urea cycle,0.038334113,3.0,0.038334113,0.32040188,0.6235771
Utilization of Ketone Bodies,0.0018930426,3.0,0.0018930426,-0.23661758,0.20669979
VEGF binds to VEGFR leading to receptor dimerization,2.86017e-06,6.0,2.86017e-06,-0.26550993,0.06666901
VEGFR2 mediated cell proliferation,0.0007316128,13.0,0.0007316128,-0.2543706,-0.20127842
VEGFR2 mediated vascular permeability,0.0042379685,21.0,0.0042379685,-0.20077425,-0.4769199
VLDL assembly,0.0,1.0,0.0,-0.26555365,0.26398215
VLDL clearance,7.2164096e-07,3.0,7.2164096e-07,-0.26554266,0.18505205
VLDLR internalisation and degradation,4.4333123e-05,8.0,4.4333123e-05,-0.264876,-0.0117948735
Variant SLC6A14 may confer susceptibility towards obesity,0.0,1.0,0.0,-0.26555365,0.26398215
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0,0.0,-0.26555365,0.26398215
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0,0.0,-0.26555365,0.26398215
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0,0.0,-0.26555365,0.26398215
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0,0.0,-0.26555365,0.26398215
Vasopressin regulates renal water homeostasis via Aquaporins,0.023841241,27.0,0.023841241,0.098871306,-0.48947802
Vif-mediated degradation of APOBEC3G,0.0010743113,35.0,0.0010743113,-0.2491323,-1.0656797
Virus Assembly and Release,0.0,1.0,0.0,-0.26555365,0.26398215
Vitamin B1 (thiamin) metabolism,0.0011099086,6.0,0.0011099086,-0.24858816,0.07933339
Vitamin B2 (riboflavin) metabolism,0.012059508,6.0,0.012059508,-0.08121822,0.20459425
Vitamin C (ascorbate) metabolism,0.0156953,4.0,0.0156953,-0.02564337,0.32512522
Vitamin D (calciferol) metabolism,0.57773274,9.0,0.57773274,8.565372,6.557357
Vitamin E,6.104953e-07,2.0,6.104953e-07,-0.26554433,0.22451994
Vitamins,0.0033477803,3.0,0.0033477803,-0.2143812,0.22334163
Vitamins B6 activation to pyridoxal phosphate,0.0,2.0,0.0,-0.26555365,0.22451296
Voltage gated Potassium channels,0.0026778819,18.0,0.0026778819,-0.22462094,-0.3763594
Vpu mediated degradation of CD4,0.002255172,34.0,0.002255172,-0.23108226,-1.0127019
VxPx cargo-targeting to cilium,0.0013645346,18.0,0.0013645346,-0.24469608,-0.3913838
WNT ligand biogenesis and trafficking,0.05187437,13.0,0.05187437,0.5273713,0.3837828
WNT ligand secretion is abrogated by the PORCN inhibitor LGK974,0.0,1.0,0.0,-0.26555365,0.26398215
WNT mediated activation of DVL,0.001177675,7.0,0.001177675,-0.24755234,0.040639434
"WNT5A-dependent internalization of FZD2, FZD5 and ROR2",0.00014118396,4.0,0.00014118396,-0.26339558,0.14718975
WNT5A-dependent internalization of FZD4,0.0014924261,9.0,0.0014924261,-0.24274121,-0.034698226
Wax biosynthesis,8.5124804e-05,3.0,8.5124804e-05,-0.26425248,0.18601762
"XAV939 inhibits tankyrase, stabilizing AXIN",2.8178178e-05,3.0,2.8178178e-05,-0.26512295,0.18536614
XBP1(S) activates chaperone genes,0.0004341582,33.0,0.0004341582,-0.25891733,-0.9940646
Xenobiotics,2.941464e-05,8.0,2.941464e-05,-0.26510403,-0.011965544
YAP1- and WWTR1 (TAZ)-stimulated gene expression,0.0086632855,7.0,0.0086632855,-0.13313113,0.12627308
Zinc transporters,0.0010847286,9.0,0.0010847286,-0.24897306,-0.039362192
alpha-linolenic acid (ALA) metabolism,0.024803562,8.0,0.024803562,0.113580845,0.27144495
c-src mediated regulation of Cx43 function and closure of gap junctions,7.0256436e-05,3.0,7.0256436e-05,-0.26447976,0.18584752
cGMP effects,0.00012258065,5.0,0.00012258065,-0.26367995,0.10750774
eNOS activation,0.0008135961,10.0,0.0008135961,-0.25311744,-0.08193303
mRNA 3'-end processing,0.09751766,49.0,0.09751766,1.2250512,-0.51495874
mRNA Capping,0.0049899085,24.0,0.0049899085,-0.18928048,-0.58672535
mRNA Splicing - Major Pathway,0.07975679,139.0,0.0005737899,-0.256783,-4.2703643
mRNA Splicing - Minor Pathway,0.00079617306,38.0,0.00079617306,-0.2533838,-1.1872691
mRNA decay by 3' to 5' exoribonuclease,0.13247763,14.0,0.13247763,1.7594312,1.2663962
mRNA decay by 5' to 3' exoribonuclease,0.0076736147,12.0,0.0076736147,-0.14825873,-0.08239437
mTORC1-mediated signalling,0.00034405102,12.0,0.00034405102,-0.26029468,-0.16624288
mitochondrial fatty acid beta-oxidation of saturated fatty acids,0.024282962,9.0,0.024282962,0.10562322,0.22602022
mitochondrial fatty acid beta-oxidation of unsaturated fatty acids,0.0005782662,2.0,0.0005782662,-0.25671458,0.23112817
p130Cas linkage to MAPK signaling for integrins,0.004652472,11.0,0.004652472,-0.19443837,-0.07748636
p53-Dependent G1 DNA Damage Response,0.008063928,42.0,0.008063928,-0.1422926,-1.2620043
p53-Independent DNA Damage Response,0.012835972,35.0,0.012835972,-0.06934959,-0.9311291
p75NTR negatively regulates cell cycle via SC1,0.00020696224,5.0,0.00020696224,-0.26239014,0.108473055
p75NTR recruits signalling complexes,0.00019941712,10.0,0.00019941712,-0.26250547,-0.08895911
rRNA modification in the mitochondrion,0.0004284945,5.0,0.0004284945,-0.2590039,0.11100733
rRNA modification in the nucleus and cytosol,0.03696793,41.0,0.03696793,0.29951912,-0.89188015
snRNP Assembly,0.07939722,12.0,0.07939722,0.9480714,0.7381069
tRNA modification in the mitochondrion,0.00042375462,6.0,0.00042375462,-0.25907636,0.071483955
tRNA processing in the mitochondrion,1.1824187e-07,2.0,1.1824187e-07,-0.26555187,0.22451429
tRNA processing in the nucleus,0.0005532465,41.0,0.0005532465,-0.257097,-1.3084557
via Dependence Receptors in the absence of ligand,0.057726786,10.0,0.057726786,0.6168283,0.56914055
